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ABSTRACT 
 
Systematic Investigation of Hydrogel Material Properties on Cell Responses for Vocal 
Fold and Vascular Graft Tissue Engineering.  (August 2009) 
  Allen Bulick, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Mariah Hahn 
  
 The research presented here deals with synthetic materials for application in 
tissue engineering, primarily poly(ethylene glycol) (PEG) and poly(dimethyl siloxane)star 
(PDMS)star.  Tissue engineering seeks to repair or replace damaged tissue through 
implantation of cell encapsulated in an artificial scaffold.  Cell differentiation and 
extracellular matrix (ECM) deposition can be influenced through a wide variety of in 
vitro culture techniques including biochemical stimuli, cell-cell interactions, mechanical 
conditioning and scaffold physical properties.  In order to systematically optimize in 
vitro conditions for tissue engineering experiments, the individual effects of these 
different components must be studied.  PEG hydrogels are a suitable scaffold for this 
because of their biocompatibility and biological “blank slate” nature. 
 This dissertation presents data investigating: the effects of glycosaminoglycans 
(GAGs) as biochemical stimuli on pig vocal fold fibroblasts (PVFfs); the effects of 
mechanical conditioning and cell-cell interactions on smooth muscle cells (SMCs); and 
the effects of scaffold physical properties on SMCs.  Results show that GAGs influence 
PVFf behavior and are an important component in scaffold design.  Hyaluronic acid 
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(HA) formulations showed similar production in collagen I and III as well as reduced 
levels of smooth muscle α-actin (SMα-actin), while chondroitin sulfate (CSC) and 
heparin sulfate showed enriched collagen III environments with enhanced expression of 
SMα-actin. 
 A physiological flow system was developed to give comprehensive control over 
in vitro mechanical conditioning on TEVGs.  Experiments performed on SMCs involved 
creating multi-layered TEVGs to mimic natural vascular tissue.  Constructs subjected to 
mechanical conditioning with an endothelial cell (EC) layer showed enhanced 
expression of SMC differentiation markers calponin h1 and myocardin and enhanced 
deposition of elastin.  Consistent with other studies, EC presence diminished overall 
collagen production and collagen I, specifically. 
 Novel PDMSstar-PEG hydrogels were studied to investigate the effects of 
inorganic content on mesenchymal stem cell differentiation for use in TEVGs.  Results 
agree with previous observations showing that a ratio of 5:95 PDMSstar: PEG by weight 
enhances SMC differentiation markers; however, statistically significant conclusions 
could not be made.  By studying and optimizing in vitro culture conditions including 
scaffold properties, mechanical conditioning and multi-layered cell-cell interactions, 
TEVGs can be designed to maximize SMC differentiation and ECM production. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Overview 
  
 Tissue engineering is a constantly expanding and developing field.  Currently, 
there exist a multitude of treatments with both natural and synthetic materials.  The 
research presented here deals with synthetic materials for application in tissue 
engineering, primarily poly(ethylene glycol) (PEG) and poly(dimethyl siloxane)star 
(PDMS)star.  The typical modern definition of tissue engineering can be attributed to 
Langer and Vacanti, where they stated that tissue engineering is “an interdisciplinary 
field that applies the principles of engineering and the life sciences toward the 
development of biological substitutes that restore, maintain or improve tissue function 
(1).”  Typically, tissue engineering is conducted by creating a scaffold with requisite 
mechanical properties, implanting cells into that scaffold, and using it to replace 
damaged tissue.  Some treatments without cell encapsulation that rely on the migration 
of native cells into the artificial scaffold have also been developed (2-4).  Many of the 
earliest successes in tissue engineering were related to skin grafts, but recent advances 
have broadened the impact to areas such as cartilage regeneration, bone regeneration and 
vascular grafts (5-7). 
 
This dissertation follows the style of Science. 
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From whichever material the scaffold is created, it must provide the bulk of the 
mechanical strength of the replaced tissue until the cells have created enough natural 
extracellular matrix (ECM) to replace the synthetic scaffold (8).  Synthetic materials are 
generally more flexible and yield greater control over their mechanical properties than 
their natural counterparts (8).  There are many ways to achieve the desired physical 
properties, and scaffolds come in a variety of forms including hydrogels, porous blocks, 
fibrous bundles, or custom shapes.  Most of the forms are achieved through some type of 
crosslinking.  Several crosslinking methods exist including chemical, physical and 
biological (9-15).  The research presented here utilizes chemical crosslinking to generate 
hydrogel scaffolds.  Figure 1.1 illustrates the different forms of the synthetic scaffolds 
(8). 
 
 
Figure 1.1:  Crosslinking mechanisms and scaffold forms in tissue engineering (8) 
 
 Utilizing the PEG and PDMSstar-PEG co-hydrogels, this research will focus on 
two areas of tissue engineering; namely, vocal fold regeneration and tissue engineered 
vascular grafts (TEVGs).  Several methods will be employed to explore the various 
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components that have been found to influence cell behavior.  Specifically, these include: 
biochemical stimuli, mechanical conditioning, cell-cell interactions and scaffold physical 
properties. 
 
1.2 Vocal Folds 
 
1.2.1 Motivation 
 
The vocal folds are a unique tissue in relation to both the frequency (100-
1000Hz) and amplitude (~1mm or 30% strain) of vibrations, causing accelerations of 
200-300g.  Voice production is heavily dependent on the biomechanical properties of the 
surrounding tissue and ECM (16, 17).  As a laminated structure, it is composed primarily 
of a stratified squamos epithelium, lamina propria and a thyroarytenoid muscle.  In 
phonation, the lamina propria, or connective tissue layer, exhibits a significant effect due 
to its viscoelastic properties.  The lamina propria is primarily composed of fibrous 
proteins, e.g. elastin and collagen, and various interstitial proteins such as 
glycosaminoglycans (GAGs), e.g. hyaluronic acid (HA) and heparin sulfate (HS).  These 
proteins are important contributors to biomechanics controlling strength, elasticity and 
viscosity (16-18).  Figure 1.2 shows a diagram of the typical vocal fold structure (17). 
Damage to the superficial lamina propria (SLP) can be caused be a multitude of 
factors such as laryngeal cancer and excessive voice strain leading to problems 
manifested in ways such as nodules, polyps and other deformities.  Upon healing, the 
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SLP is left scarred which can affect the ability for phonation by changing the 
biomechanical properties of the remaining tissue.  Various speech and voice disorders of 
this nature have been shown to affect ~3-5% of the population, and there is yet a suitable 
method for repairing the damaged (16-18).  Methods currently in use include physical 
therapy and surgery by implantation of synthetic or natural ECMs such as collagen and 
Teflon (19-23).   
 
 
Figure 1.2: Structure and makeup of vocal fold tissue (17) 
 
1.2.2 Research 
 
Tissue engineering now has a role in creating new materials for implantation to 
assist in repair to the damaged and scarred areas of the lamina propria.  Tissue 
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engineering methods under study range from natural ECMs (collagen, HA and 
derivatives) to synthetic (poly(lactic acid) (PLA), poly(glycolic acid) (PLG), PEG as 
well as xenogenic (porcine) ).  Together, the SLP and surrounding epithelium comprise 
the mucosa whose altered viscoelastic properties lead to the many voice disorders.  
Vocal fold tissue has three main cellular components, namely:  myofibroblasts, 
microphages and fibroblasts.  The vocal fold fibroblasts maintain the lamina propria and 
participate in the replacement and manufacture of new fibrous and interstitial proteins 
(18-20, 22, 24).   
PEG is an attractive choice among the synthetic ECMs in that its non-biofouling 
properties render it a “blank slate” material, facilitating the study of cellular response 
without effects from the environment (25).  It can also be modified to allow for 
photocrosslinking (PEG diacrylate (DA)) and to include biochemically active proteins 
such as GAGs and proteoglycans (26-28).  An example of this is included in Figure 1.3 
(28).  In order to engineer materials for vocal fold repair, cellular response in a synthetic 
ECM must be optimized.  This can be done by individually studying the various effects 
of components from natural vocal fold tissue on cellular production and response.  The 
work presented here concerns in vitro 3D culture of pig vocal fold fibroblasts (PVFf) in 
PEGDA with four GAGs found to participate in vocal fold tissue.  The four GAGs 
chosen include the widely studied HA, as well as HS, dermatan sulfate (DS) and 
chondroitin sulfate C (CSC) (22, 29-32).  PVFf were encapsulated with one of the 
specified GAGs and cultured in vivo for a period of 2.5 weeks.  After sample collection, 
the cells were characterized quantitatively and qualitatively for ECM deposition of 
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elastin, collagen type I and III.  DNA was also measured as a means to determine cell 
viability through culture. 
 
 
Figure 1.3:  Reaction scheme for a PEG hydrogel functionalized with CSC (28) 
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1.3 Tissue Engineered Vascular Grafts 
 
1.3.1 Motivation 
 
 Cardiovascular disease is the leading cause of fatalities world wide across every 
demographic.  Arterial bypass surgeries are commonplace and one of the main methods 
of alleviating atherosclerosis and other conditions.  Approximately 500,000 of these 
procedures are performed in the US annually (33).  The synthetic materials Dacron and 
Teflon have been successfully used in large diameter arterial replacement applications.  
However, due to several issues, these materials, as well as attempts with other methods, 
have met with little success when dealing with small diameter (<6mm) vasculature (34).  
The main reasons for TEVG failure in the past have been one or a combination of:  
thrombosis due to lack of a compatible endothelium, restenosis due to inflammatory 
response and infection and mechanical failure due to lack of sufficient strength.  
Synthetic materials have high occlusion at lower diameters and attempts for implantation 
of TEVGs made from natural sources, such as collagen, have experienced problems 
maintaining sufficient tensile strength in vivo (35-37).   
 Successful TEVGs must address the shortcomings of past attempts.  Namely, 
they must be able to withstand the shear and cyclic stresses experienced in vivo and 
abstain from inducing an inflammatory response.  This has led to the development of 
TEVGs in vitro in an attempt to prepare them for in vivo implantation (6).  Most work 
has focused on the medial layer of vascular tissue, composed and maintained by smooth 
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muscle cells (SMCs) (38-41).  In order to develop functional TEVGs suitable for use in 
vivo, the SMCs must be conditioned in such a way so that they may produce their own 
ECM to replace the damaged vascular tissue in the body.  By accomplishing this, 
TEVGs may address some limitations of natural source grafts that did not have sufficient 
mechanical properties similar to that of the native vascular tissue.  The SMC layer is 
buttressed by an inner endothelial layer and an outer adventitial layer, composed of 
fibroblasts.  A cross-section of a blood vessel showing the multi-layered architecture is 
shown in Figure 1.4 (42).   
 Investigations into the variables affecting medial layer development have 
independently confirmed the importance of a wide variety of components.  These 
variables can be arranged into two subgroups.  Group 1 consists of the scaffold in which 
the cells are seeded; specifically its biochemical, mechanical and morphological 
properties.  Group 2 consists of in vitro development conditions, i.e. mechanical 
conditioning and cell-cell interactions.  Studies of multi-cell layered constructs under 
mechanical conditioning in vitro have been limited.  This is an important subsequent 
step in the development of these grafts as cell-cell interactions may differ in the presence 
of conditioning.  The long-term desire of TEVGs is to have the artificial scaffold 
degrade as it is replaced by the natural ECM of the encapsulated cells.  Initially, 
however, the synthetic scaffold has a large influence on cell activity; therefore, 
optimizing its properties such as mesh size and elastic modulus are important.  The 
central hypothesis of this work is that we can modulate SMC behavior, differentiation 
and ECM production by optimizing its in vitro culture conditions. 
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Figure 1.4: Structure of a blood vessel (42) 
 
1.3.2 Research 
 
The goal of this research is to elucidate and optimize the combinatorial effects of 
scaffold properties and in vitro culture conditions on SMC ECM production and 
differentiation.  Specifically, we will investigate: 
• Material properties including inorganic content and elastic modulus 
• Effects of mechanical conditioning and cell-cell interactions 
  Development of technology in this area benefits from a large patient base as 
well as the potential to save lives.  Variables from group 2 consist of mechanical 
conditioning and cell-cell interactions.  In vivo, cells experience both cyclic tensile strain 
and transmural shear stress.  Research studying the influence of both types of these 
forces has been limited, and most experiments involving shear stress were comprised of 
direct instead of transmural shear stress (43, 44).  Cell-cell interactions can be introduced 
by multi-layered TEVGs with multiple cell types.  In order to investigate the variables 
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from group 2, a physiological flow system is needed to mimic the natural conditions 
experienced by SMCs in vivo.  A multi-layered TEVG with the endothelial and medial 
layers has been studied under physiological flow conditions, but not in such a way as to 
decouple the effects of each independent variable (45). 
 Scaffold properties such as mesh size, elastic modulus and degradation rates have 
all been shown to impact cell activity and the selection of a synthetic scaffold is 
extremely important in order to study all of the pertinent variables (46, 47).  PEG 
hydrogels have both the requisite chemical and physical properties necessary for this 
research.  It is hydrophilic and biocompatible.  PEG is permitted for use in vivo and has 
the further benefit of being non-biofouling, meaning it will not adsorb proteins from 
solution, allowing us to attribute cellular response specifically to the signaling proteins 
we introduce (25).  One limitation of PEG hydrogels is that encapsulated cells, even 
when presented with a scaffold adhesion ligand like RGDS, take on a rounded 
morphology.  Normally, in vivo, healthy cell have an elongated phenotype.  In hydrogel 
chemistry, PEG end groups can be modified with acrylate groups yielding PEG 
diacrylate (PEGDA) for photopolymerized crosslinking.  This is advantageous because 
PEG hydrogels can be formed in vitro and implanted, or solution-injected and formed in 
vivo.  PEG is chemically modifiable through addition of acrylate molecules, facilitating 
addition of ECM signaling components such as glycosaminoglycans (GAGs) (27).  PEG 
can also be copolymerized with other monomers such as poly(lactic acid) (PLA) and 
poly(glycolic acid) (PLG) to yield biodegradable gels.  Hybrid gels can also be formed 
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with other polymers such as PDMSstar to alter mechanical properties and hydrophilicity 
(25).   
To characterize the SMC phenotype, this research will focus on the serum 
response factor (SRF), a transcription factor and member of the MADS-box family.  
SRF has been shown to regulate many contractile proteins of SMCs and participates in 
many cell functions such as proliferation, apoptosis and differentiation.  SRF and its 
binding partners associated with SMCs, myocardin and pelk-1, will give an indication of 
cell activity and whether it is more directed towards proliferation or differentiation (48).  
Myocardin has been associated with expression of calponin h1, a late term marker for 
SMC differentiation, while pelk-1 has been shown to have a role in cell growth (49, 50).  
In addition, the efficacy of the different external stimuli will also be assessed by ECM 
production (collagen and elastin). 
 
1.3.3 Background 
 
 Because of the necessity of small diameter vascular tissue replacement and its 
implications in prolonging life, TEVGs are of growing interest in the biomedical 
community.  TEVGs as a concept were introduced by Weinberg and Bell when they 
created cell-seeded collagen gel tubes (51).  This early work was hindered by the need 
for a synthetic, non-removable support for the tubes.  Subsequent attempts also 
experienced limiting mechanical properties (52, 53).  The first clinical application was 
achieved by Shin’oka et al using autologous bone marrow cells encapsulated into a 
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construct created from the biodegradable polymers L-lactide and ε-caprolactone (54).  
These succeeded in low-pressure applications mainly in pediatric patients, but could not 
be extended to adults and higher pressures.  TEVGs for implantation in these systems 
need mechanical strength similar to that of native tissue and must be able to withstand 
pressures of  >1700mmHg (36).  They must also be resistant to fatigue since they are 
exposed to constant cyclic and shear stresses.  These factors necessitate the pre-
conditioning of SMCs in a synthetic scaffold until they can produce enough natural 
ECM for stable implantation.   
Studies performed with cyclic strain have shown increases in the markers myosin 
heavy chain (MHC) and h-caldesmon as well as enhanced cell proliferation, all 
indicative of a more mature phenotype (55, 56).  ECM production (i.e. elastin and 
collagen) was also upregulated in the presence of cyclic strain (57, 58).  Transforming 
growth factor-β1 (TGF-β1), platelet derived growth factor (PDGF) and vascular derived 
growth factor (VEGF) were also upregulated in response to cyclic strain (59, 60).  PDGF 
and VEGF are an important growth factors involved in angiogenesis.  While few studies 
mimicking the indirect shear stress experienced by SMCs in vivo have been performed, 
some with direct shear have shown significant influence on SMC behavior (43, 44).  It 
has been shown that matrix metalloprotease-2 (MMP-2), an enzyme linked to abnormal 
cell migration, is down regulated while TGF-β1, a major controller of proliferation and 
differentiation, was upregulated (43, 44).  Cell-cell interaction studies have also 
confirmed that in the presence of endothelial cells (ECs) SMCs show increased levels of 
TGF-β1, PDGF and VEGF (43).  Basic fibroblast growth factor (bFGF) is thought to be 
13 
the key component of embryonic stem cell (eSC) medium acting to maintain the eSCs in 
an undifferentiated state.  Co-culture of SMCs with ECs show decreased levels of this 
growth factor, suggesting a lowered inhibition to differentiation, leading to a more 
mature phenotype (55, 56). 
Past studies on the influence of scaffold mechanical properties have indicated a 
correlation between modulus and mesh size on cell behavior (46, 47).  However, these 
studies were not able to sufficiently decouple the mechanical properties from the 
biochemical ones.  In one instance, scaffold mechanical properties were altered by 
changing the collagen density in the framework (61).  Unfortunately, the modulation of 
collagen density also changes the bioactivity of the scaffold; meaning that 
comprehensive conclusions as to the actual cause of the changes in cell behavior could 
not be attributed solely to the change in modulus.  In analyzing cell responses to 
alterations in specific material properties, we will focus on conventional measures of cell 
ECM deposition and the SRF pathway as a regulator of SMC phenotype.  The SRF 
pathway is an appropriate system to study SMC phenotype and ECM production.  Many 
signaling pathways such as RhoA, TGF-β and MAPK modulate SRF activity, which can 
control both differentiation and proliferation independently, depending on the presence 
of particular binding partners (59, 60).  Myocardin, one such binding partner is a master 
regulator of SMC gene expression that inhibits differentiation towards skeletal muscle 
and cell proliferation and will be investigated (62).  Figure 1.5 is a diagram outlining the 
path of SMC differentiation from an undifferentiated mesenchyme and shows important 
early and late-term differentiation markers. 
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The choice of a cell source is of particular importance when designing TEVGs.  
The first choice would be vascular smooth muscle cells harvested from the patient.  
However, due to several factors including persistent disease, hyperplasia and tissue 
damage, this is not always an option (63).  Secondly, cells from appropriate animal 
models could fulfill the demand where autologous cells are unavailable.  Common small 
and large animal models for vascular tissue are rat and pig, respectively.  This is also a 
non-ideal solution given the possibility of an immunoresponse to a foreign cell line.  The 
next logical step would be to harvest a cell type that is undifferentiated, but capable of 
developing into SMCs upon application of appropriate stimuli.  Mesenchymal stem cells 
(MSCs) fulfill this requisite and can be harvested from various sources within the patient 
(64, 65).  
 
 
 
Figure 1.5:  SMC differentiation pathway 
 
A common source for MSCs is bone marrow.  However, hindrances such as viral 
infection and decreased cell count with advanced age require other sources to be 
explored.  Advances in harvesting techniques have led to the isolation of MSCs from 
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many sources such as vascular tissue, umbilical chord blood and processed adipose 
tissue.  MSCs have been shown to differentiate along a myriad of cell lines including 
osteoblasts, chondrocytes, adipocytes and myocytes (63-65).  Factors shown to influence 
SMC behavior and differentiation have also been shown to influence MSC 
differentiation to SMC (63, 66-69).  These factors include mechanical stimulation, co-
culture with ECs, and exposure to the relevant growth factors and biochemical stimuli.  
Through the application of previously discussed methods including optimization of 
artificial scaffold, mechanical conditioning, biochemical interactions and cell-cell 
interactions, we can selectively differentiate MSCs to SMCs in vitro and further 
optimize their performance as SMCs. 
 
1.3.4 PDMSstar-PEG Co-Hydrogels 
 
 PDMSstar materials were developed by the Grunlan group and studied in 
conjunction with the Hahn group.  PDMS can be chemically modified to form 
crosslinking units similar to those of PEG, allowing for its incorporation into the 
hydrogel framework.  The addition of PDMS significantly expands the range achievable 
mechanical properties over PEG hydrogels alone.  It is hypothesized that this enhanced 
range of mechanical properties can be achieved without sacrificing the anti-biofouling 
nature of pure PEG, while introducing control over other scaffold properties including 
hydrophilicity and elastic modulus.  In previous work, amphiphilic materials, such as the 
one proposed here, have exhibited an ability to limit interaction with biofoulers (70).  In 
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general, systematic control over these properties will be achieved by adjusting the 
weight ratios of the two polymers in solution.  PDMSstar materials were chosen over a 
linear molecule because the shape may assist in limiting phase separation between 
hydrophilic and hydrophobic components (71).  Figure 1.6 (72) shows the co-hydrogels 
maintaining the non-biofouling property and Figure 1.7 shows a reaction scheme of the 
formation of PDMSstar polymers (73, 74). 
 
 
 
 
 
Figure 1.6: Cell spreading on hydrogels: A: pure PEG B: PDMSs-PEG C: PDMSstar-PEG with 
1µmol/mL of RGDS adhesion peptide (72) 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Reaction pathway for production of PDMSstar diacrylate (73, 74) 
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Previous work with varying ratios of PDMSstar-PEG, specifically 6 kDa PEG 
combined in 1:99, 5:95 and 10:90 weight ratios (PDMSstar:PEG) with 1.8 kDa, 5 kDa 
and 7 kDa MW PDMSstar, showed a degree of control over the mechanical properties as 
well as swelling ratios (indicative of material hydrophilicity).  Contrary to what was 
expected, an increase in MW of PDMSstar in the hydrogel resulted in an increase in water 
uptake.  The most likely cause of this is the larger molecular weight resulting in a lower 
crosslinking density, thereby allowing for greater water absorption.   
 Preliminary studies also showed differences in extracellular matrix production 
and expression of differentiation markers.  In general, the 5:95 hydrogels showed 
significant differences from pure PEG in increased collagen and elastin production as 
well as expression of calponin h1.  The other ratios did not show significant differences 
in extracellular matrix production, but did exhibit differences in the expression of SRF 
pathway related genes; namely, SRF, calponin h1 and SM γ-actin.  The results also 
suggest a correlation between scaffold modulus and SRF pathway gene expression, 
consistent with previous studies showing a link between modulus and cell behavior.  In 
an effort to expand on these studies, an expanded property space investigating a wide 
range of scaffold moduli and swelling ratios is proposed.  This expanded property space 
is represented graphically in Figure 1.8.  The mechanical properties span above and 
below the modulus of native vascular tissue, allowing for the development of optimal in 
vitro culture conditions. 
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Figure 1.8: 2D property space for PDMSstar-PEG co-hydrogels with formulations of interest circled 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Introduction 
  
 There are many components to consider when analyzing these tissue engineering 
experiments.  Cell behavior can be characterized in many ways including ECM 
production and deposition along with gene expression.  For experiments in which 
scaffold physical properties are important, these must also be measured.  Techniques for 
analyzing results include histological staining, biochemical assays, reverse transcription-
polymerase chain reaction (RT-PCR), Instron tensile testing, and nuclear magnetic 
resonance (NMR).  An example NMR spectrum showing the relevant peaks used to 
prove acrylation is shown in Figure 2.1.  Histological staining will be used to 
qualitatively and semi-quantitatively assess ECM deposition and gene expression.  
Biochemical assays will provide a quantitative measure of the same.  RT-PCR gives 
insight into gene expression and related transcription pathways.  An Instron 3342 
mechanical testing device with a 10N load cell was used to determine the mechanical 
properties of the hydrogel scaffolds and NMR was employed to calculate the acrylation 
efficiency as a measure of crosslinking efficiency. 
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Figure 2.1:  Example NMR spectra for PEG acrylation 
  
 This research includes: an experiment investigating the impact of biochemical 
stimuli of GAGs on pig vocal fold fibroblasts (PVFf); three experiments utilizing a 
physiological bioreactor system to investigate the impact of cell-cell interactions and 
mechanical conditioning on SMCs in TEVGs; and an experiment employing PDMSstar-
PEG co-hydrogels to measure the impact of scaffold physical properties including elastic 
 
Acrylate Peaks 
PEG Peak 
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modulus and inorganic content on SMCs for use in TEVGs.  General methods for 
experimental techniques will be presented along with notations for specific experiments 
where necessary. 
 
2.2 PEGDA Synthesis 
 
PEGDA was prepared as previously described by combining 0.1 mmol/ml dry 
PEG, 0.4 mmol/ml acryloyl chloride, and 0.2 mmol/ml triethylamine in anhydrous 
dichloromethane and stirring under argon overnight (75).  PEGDA of MW 6kDa and 
3.4kDa were prepared via this method for use in experiments.  The resulting solution 
was washed with 2 M K2CO3 and separated into aqueous and DCM phases to remove 
HCl. The DCM phase was subsequently dried with anhydrous MgSO4, and PEGDA was 
precipitated in diethyl ether, filtered, and dried under vacuum. 
Cell adhesion peptide RGDS was conjugated to acryloyl-PEG-N-
hydroxysuccinimide (ACRL-PEG-NHS) at a 1:1 molar ratio for 2 h in 50 mM sodium 
bicarbonate buffer, pH 8.5 (75).  The product (ACRL-PEG-RGDS) was purified by 
dialysis, lyophilized, and stored at -20 ºC until use. 
 
2.3 PDMSstarMA Synthesis 
 
PDMSstar methacrylate (PDMSstarMA) samples were developed and prepared by 
the Grunlan group.  A graphical representation was shown in Figure 1.7 (73, 74).  All 
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reactions to synthesize methacrylated star PDMS were run under a N2 atmosphere with a 
Teflon-covered stir bar to agitate the reaction mixture.  MWs of 1.8, 5 and 7kDa were 
prepared.  Octamethylcyclotetrasiloxane (D4) was combined with 
tetrakis(dimethylsiloxy)silane (tetra-SiH) in a 200mL round bottom flask and purged 
with N2 for 5mins.  They were then reacted by acid catalysis by adding triflic acid to the 
mixture quickly with stirring for 16h at room temperature (RT).  After neutralization 
with hexamethyldisilazane (HMDS), the polymer was dissolved in minimal toluene and 
precipitated in methanol (MeOH) at a ratio of 3:1 MeOH:toluene, then dried under 
vacuum (73, 74).  
To methacrylate the end groups of the PDMSstarSiH polymers, they were first 
dissolved in 20-35mL of toluene and purged with N2 in a 250mL round bottom flask.  
The temperature was raised to 45°C and allyl methacrylate was added dropwise.  After 
raising the solution to 90°C, Karstead’s catalyst was added quickly and the mixture was 
stirred overnight while maintaining the temperature at 90°C (76, 77).  The final 
PDMSstarMA product needed to be purified and collected.  To accomplish this, flash 
column chromatography was used with a hexanes:ethyl acetate ratio of 2:1 vol:vol, with 
volatiles removed under reduced pressure.  Table 2.1 shows the amounts of reagents 
used for each desired molecular weight with their subsequent yield of PDMSstarSiH.  
Table 2.2 shows the amounts of reagents used to produce PDMSstarMA for each 
molecular weight and their subsequent yields. 
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Table 2.1: Reagents and yields for synthesis of PDMSstarSiH 
PDMSstarSiH 
MWdesired 
(kDa) 
D4 
(g/mmol) 
tetra-SiH 
(g/mmol) 
triflic acid 
(µL) 
HMDS 
(g) 
MWobtained 
(kDa) yield 
1.8 30/100 7.8/24 60 0.15 1.8 61% 
5 29.9/100 1.7/5 60 0.15 4.6 75% 
7 29.9/100 1.1/3.3 60 0.15 6.8 79% 
 
 
Table 2.2: Reagents and yields for synthesis of PDMSstarMA 
PDMSstarMA 
MWdesired 
(kDa) 
allyl 
methacrylate 
(g/mmol) 
toluene 
(mL) 
Karstedt's 
catalyst (µL) yield 
1.8 0.42/3.3 35 100 75% 
5 1.3/10.2 35 100 94.40% 
7 1.6/12.3 35 100 80% 
 
2.4 Cell Culture 
 
The experiments presented here utilized four different cell lines: PVFfs (Cell 
Applications), rat aortic SMCs (RASMCs Cell Applications), bovine aortic ECs (BAEC, 
Cell Applications), 3T3 fibroblasts (Cell Applications) and 10T1/2 mesenchymal stem 
cells (Cell Applications).  Each line was thawed and expanded at 37°C and 5% CO2.  
The cells were cultured in Dulbecco`s Modified Eagle`s Media (DMEM, Hyclone, 
Logan) with 10% iron supplemented bovine calf serum (BCS, Hyclone).  In addition, 
PVFfs, RASMCs and BAECs were cultured with 100 mU/mL penicillin, and 100 mg/L 
streptomycin (Hyclone).  A potential concern with using cell lines from different species 
is a reduction in cell-cell communication, which in TEVGs is an important component in 
cell behavior.  However, this facilitates an easier isolation of cell line effects if cell 
24 
migration between layers should occur.  RASMCs and BAECs have been used co-
currently in many other model systems to study SMC and EC behavior (78-80).   
 
2.5 Hydrogel Preparation, Encapsulation and Maintenance 
 
2.5.1 Vocal Fold Experiment 
 
Hydrogel precursor solutions were prepared with 0.1g/mL 10kDa PEGDA and 
1µmol/mol ACRYL-PEG-RGDS in HBS (10mM HEPES, 150mM NaCl, pH 7.4) (75) 
and sterilized by filtration.  With this procedure, four precursor solutions were prepared, 
and to one precursor solution each, CSC, HA, HS and DS were added at 1mg/mL.  In 
addition, 10µL/mL of a 300 mg/mL solution of UV photoinitiator 2,2-dimethoxy-2-
phenyl-acetophenone (acetophenone, Sigma) dissolved in N-vinylpyrrolidone (Sigma) 
were added to each solution.  PVFfs at passage 8-10 were washed with phosphate 
buffered saline (PBS), harvested and suspended at 1.6x106 cells/mL in the hydrogel 
precursor solutions.  Precursor solutions were then loaded into a flat plate geometry with 
a thickness of 1.1mm and photopolymerized under UV light (365 nm, ~10 m mW/cm2, 
UVP model B-100SP, Upland) for 2 mins (1min/side).  The hydrogel were transferred to 
Omnitrays (Nunc) fitted with 4 sterile polycarbonate bars to simultaneously prevent gel 
flotation and prevent gel contact with the tray bottom.  Gels were immersed in DMEM 
supplemented with 10% BCS, 100 µU/mL penicillin, and 100 mg/L streptomycin and 
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maintained at 37 ºC/5% CO2 for a period of 17 days.  Media was changed every two 
days until samples were harvested for analysis. 
 
2.5.2 TEVG Experiments 
 
 All bioreactor experiments consisted of multi-layered cylindrical constructs.  
Bioreactors I and II were dual layered experiments utilizing the SMC and EC layers.  
Bioreactor III was a tri-layered experiment with the additional 3T3 fibroblast layer.  The 
cell lines chosen have been widely used in literature as human vascular models (81-87). 
 
2.5.2.1 Bioreactor I 
 
TEVG preparation was similar to that of Bioreactor I, but differs in that instead 
of a dried monolayer of ECs, the inner layer is a hydrogel cylinder with encapsulated 
ECs.  This required a two step process.  First, RASMCs as passages 9-12 were harvested 
and resuspended at a density of 2x106 cells/mL in the PEGDA hydrogel precursor 
solution containing 0.1g/mL 6kDa PEGDA and 1µmol/mL ACRYL-PEG-RGDS in 
HBS-triethanolamine (HBS with 115mM triethanol amine (TEOA)).  Ten µl of a 300 
mg/mL solution of acetophenone  (Sigma) dissolved in N-vinylpyrrolidone (Sigma) was 
then added per mL of mixture. The resulting solution was sterilized by filtration. 
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Figure 2.2:  Dual-layered vascular graft example. A)  
Cylindrical mold for TEVG photopolymerization, 
includes Teflon bases, glass inner rod and plastic outer 
cylinder.  B)  Image of a ring segment from a tubular bi-
layered PEGDA construct containing SMC in the outer 
layer and EC in the luminal layer. The luminal layer 
appears more opaque due to the higher EC seeding 
density.  C)  TEVG cross-section showing the outer SMC 
layer with a higher cell density EC inner layer (88) 
 
 
 
RASMCs at passages 9-12 were harvested and resuspended at 2x106 cells/mL in 
the hydrogel precursor solution.  The mixture was homogenized and 0.7mL/construct 
were transferred into the UV transparent cylindrical molds, with an inner diameter of 
5mm and an outer diameter of 7.4mm.  The solution was photopolymerized under 
longwave UV light as before for 1min.  The inner 5mm rod was removed and replaced 
by a 4mm glass rod.  The constructs were divided randomly.  BAECs at passages 9-12 
were harvested and resuspended at 10x106 cells/mL in the PEGDA precursor solution.  
For the first random group, the BAEC-suspended precursor solution was added to the 
1mm inner layer at 0.21mL/construct and photopolymerized for an additional 1min.  For 
the second group, the inner layer was composed of a blank PEGDA solution containing 
no cells at the same volume/construct.  For the non-cell containing solution, a volume of 
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HBS-TEOA equal to that taken up by the cells in the first group was added to the 
precursor solution to account for volume effects of the cells.  Again, the hydrogels in the 
second group were photopolymerized for an additional 1 min. 
 The dual-layered hydrogels were removed from their molds and briefly rinsed in 
PBS containing 1% PSA.  Constructs were then immersed in DMEM containing 10% 
BCS and 1% PSA and were cultured statically at 37 ºC/5% CO2 for 3 days to ensure 
contamination did not occur.  Media was changed every day until constructs were 
collected for mechanical conditioning. 
 
2.5.2.2 Bioreactor II 
 
 TEVGs created for this experiment follow a similar procedure for those 
developed in the Bioreactor II experiment.  Additionally, there is a third cell layer to 
introduce and study the effects of 3T3 fibroblasts.  This required a three step 
polymerization process.  In addition to the added layer, the cell source will be shifted 
away from primary smooth muscle cells to the mesenchymal progenitor line, 10T1/2.  
This line was chosen for multiple reasons.  Progenitor cells show greater consistency in 
behavior over primary cells regardless of source.  10T1/2 cells are well characterized 
and, like other mesenchymal stem cells, have been shown to differentiate into many cell 
lines such as osteoblasts, chondrocytes, adipocytes and myocytes, but have shown a 
preference towards myocytes, or muscle cells (89-92).  To date, there is still skepticism 
as to whether or not 10T1/2 cells behave truly as smooth muscle cells upon 
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differentiation.  This work is intended to provide evidence that they can be successfully 
and selectively guided towards a mature SMC phenotype.  The experiment was run with 
three different configurations with three samples for each; one with all three cell types, 
one with ECs and 10T1/2 cells, and one with 10T1/2 cells only 
3T3 fibroblasts at passage 14-16 were harvested and resuspended at a 
concentration of 8.6x106 cells/mL in a PEGDA precursor solution (containing 0.1g/mL 
6kDa PEGDA and 1µmol/mL ACRYL-PEG-RGDS in HBS-TEOA).  Ten µl of a 300 
mg/mL solution of acetophenone (Sigma) dissolved in N-vinylpyrrolidone (Sigma) was 
then added per mL of mixture. The resulting solution was sterilized by filtration.  The 
solution (0.65mL) was then added to a UV transparent mold with an inner glass rod of 
diameter of 6.9mm and an outer plastic tube with a diameter of 7.4mm and 
photopolymerized under longwave UV for 1min.  For the two sets of constructs without 
a 3T3 layer, a precursor solution with HBS added in an amount equivalent to the volume 
occupied by the cells (~0.05mL) was photopolymerized as the outer layer. 
10T1/2 mesenchymal stem cells at passage 18-21 were harvested and 
resuspended at a concentration of 10x106 cells/mL in an equivalent PEGDA precursor 
solution.  The inner glass rod was removed and replaced with one of 4.5mm diameter.  
The cell-suspended precursor solution (0.55mL/gel) was then added to the cylindrical 
mold and photopolymerized for an additional 1min.  BAECs at passage 9-12 were 
harvested and resuspended at a density of 7x106 cells/mL.  For the two sets that contain 
an EC layer, the cell-suspended precursor was added to the mold with an inner diameter 
of 4mm and photopolymerized for an additional 1min.  The wall thickness of the inner 
29 
layer was reduced to half that of Bioreactor II to closer mimic the EC monolayer present 
in natural vascular tissue.  For the set not containing ECs, the inner layer was 
photopolymerized with the blank PEGDA precursor solution with an equivalent volume 
of HBS in place of the BAECs.  The tri-layered hydrogels were removed from their 
molds and briefly rinsed in PBS containing 1% PSA.  Constructs were then immersed in 
DMEM containing 10% BCS and 1% PSA and were cultured statically at 37 ºC/5% CO2 
for 3 days to ensure contamination did not occur.  Media was changed every day until 
constructs were collected for mechanical conditioning. 
 
2.5.2.3 Bioreactor III 
 
Dual-layered TEVGs were prepared with a BAEC inner layer and a RASMC 
outer layer. In the first step, BAEC cells were locked to the lumen of the construct via 
drying of the PEGDA precursor solution. Then SMC were encapsulated in the outer area 
of the tubular PEGDA hydrogels. In conducting this polymerization procedure, a 
precursor solution containing 0.1 g/mL PEGDA and 1 µmol/mL ACRL-PEG-RGDS in 
HBS-TEOA (10 mM HEPES, 150 mM NaCl, 115 mM triethanolamine, pH 7.4) was first 
prepared.  Ten µL of acetophenone  (Sigma) dissolved in N-vinylpyrrolidone (Sigma) 
was then added per mL of mixture. The resulting solution was sterilized by filtration. 
BAEC at passages 9-12 were harvested and resuspended at 30x106 cells/mL in 
PEGDA precursor solution. The resulting mixture was spread evenly on a 5mm glass rod 
(100 µL) and then placed horizontally between two cylindrical molds. Sterile air was 
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introduced, and the rod was rolled until the viscosity of the PEGDA solution increased 
substantially to ensure that the cells were anchored. This procedure was repeated to 
create a uniform monolayer of BAEC cells. The construct was then disassembled and a 
plastic cylinder (ID = 7.4 mm) was carefully placed over the glass rod. RASMC at 
passages 9-12 were harvested and resuspended at 2x106 cells/mL in an aliquot of the 
precursor solution. The resulting mixture was pipetted (~0.7 mL per construct) into the 
UV transparent cylindrical molds, and polymerization of the PEGDA precursor solution 
into the tubular hydrogels was initiated by exposure of the molds to UV light (365 nm, 
~10 m mW/cm2, UVP model B-100SP, Upland) for 2 minutes.  Figure 2.2 (88) shows 
the cylindrical mold with a dual-layered TEVG. 
The resulting hydrogels were removed from their molds and briefly rinsed in 
PBS containing 1% PSA (10 U/mL penicillin, 10 g/L streptomycin, and 10 g/L 
amphotericin (Mediatech, Manassas). Constructs were then immersed in DMEM 
containing 10% BCS and 1% PSA and were cultured statically at 37 ºC/5% CO2 for 3 
days to ensure contamination did not occur.  Media was changed every day until 
constructs were collected for mechanical conditioning. 
 
2.5.2.4 PDMSstar-PEG Hydrogels 
  
This experiment probes the effects of different scaffold physical properties by 
introducing PDMSstar into the hydrogel network to give wide control over water content, 
elastic modulus and surface morphology.  Twelve different formulations were chosen, 
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spanning the mechanical properties illustrated in Figure 1.9.  Table 2.3 shows the 
formulations that were chosen and their compositions.  For reference, 95:5 refers to a 
hydrogel with 10% overall polymer concentration in HBS-TEOA, with 95% of that 
composed of PEGDA and 5% composed of PDMSstar.  In addition, there are two 
combined formulations of 6kDa and 3.4kDa PEGDA.  These also contain an overall 
polymer concentration of 10% in HBS-TEOA.  For example, a precursor solution of 
each with an overall polymer concentration of 10% in HBS-TEOA, 3.4kDa and 6kDa 
with 5kDa PDMSstar at ratios of 99:1 and 80:20, respectively, were prepared.  These 
were then combined in equal parts to yield the formulation listed in the table.  Three 
samples for each formulation were prepared, yielding 36 total constructs (1 construct of 
the 6k/5k 90:10 formulation was discarded as a result of contamination leaving 35 total 
constructs). 
10T1/2 mesenchymal stem cells at passage 21 were harvested and resuspended at 
a density of 3x106 cells/mL in sterile-filtered precursor solutions according to Table 2.3 
with an overall polymer concentration of 10% in HBS-TEOA with 1µmol/Ml ACRYL-
PEG-RGDS.  Precursor solutions (~0.8mL) were added to UV transparent cylindrical 
molds with Teflon bases.  The molds had an outer diameter of 7.4mm with an inner 
diameter of 5mm.  Solutions were then photopolymerized in random groups of three 
under longwave UV for a period of 5 mins.  The tri-layered hydrogels were removed 
from their molds and briefly rinsed in PBS containing 1% PSA.  Constructs were then 
immersed in DMEM containing 10% BCS and 1% PSA and were cultured statically at 
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37 ºC/5% CO2 for a period of 21 days.  Media was changed every two days until samples 
were harvested for analysis. 
 
Table 2.3:  Compositions of PDMSstar-PEGDA hydrogels used to study the effects of scaffold physical 
properties on SMC behavior.  As an example of the ratios presented, 95:5 refers to an overall 10% 
polymer solution in HBS-TEOA, 95% being PEGDA and 5% being PDMSstar.  For the last two combined 
formulations, the overall polymer concentration is again 10% in HBS-TEOA, half of which is the 3.4k 
formulation and half of which is the 6k formulation 
PEGDA 
MW 
(kDa) 
PDMSstarMA 
MW (kDa) 
PEGDA:PDMSstarMA 
  
3.4 0 100:0 
  1.8 95:5 
  1.8 80:20 
  5 95:5 
  7 99:1 
  7 80:20 
6 0 100:0 
  5 90:10 
  7 80:20 
3.4,6 5 99:1, 80:20 For these formulations, solutions were 
prepared in equal amounts of the ratios shown, 
half of the 3.4k formulation and half of the 6k 
formulation 
  5 80:20, 80:20 
   
 
 
 
2.6 Mechanical Conditioning 
 
 The three bioreactor experiments include a period of mechanical conditioning to 
study its effects on SMC behavior and 10T1/2 differentiation in addition to those effects 
introduced by cell-cell interactions.  Figure 2.3 (41) shows a schematic of the 
physiological flow system used for these experiments.  The system, described previously 
(41), consists of a bioreactor chamber which houses the TEVGs, which are surrounded 
by culture media (DMEN, 10% BCS, 1% PSA).  A Masterflex L/S digital peristaltic 
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pump with two Easy Load II pump heads (Cole Palmer) generates flow by drawing 
media from the reservoir.  The media then flows through a compliance chamber 
followed by a pulsatile pump (CellMax, Spectrum Labs) which was used to overlay the 
sinusoidal waveform (Figure 2.4) (88).  Media then flowed through the inner lumen of 
the TEVG constructs to mimic the constant mechanical conditioning experienced by 
vascular tissue in vivo.   
 
 
Figure 2.3:  Physiological flow system to 
control mechanical conditioning in TEVGs.  The 
system consists of a bioreactor chamber to house 
constructs, peristaltic pump to provide flow, and 
a pulsatile pump to provide the sinusoidal 
waveform.  Reactor chamber and media reservoir 
are vented to the atmosphere to maintain 
pressure and allow for gas exchange (41) 
 
 
 
The media reservoir and reactor chamber were outfitted with sterile gas-
exchange filters to maintain an atmospheric pressure and maintain constant CO2 levels.  
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Constructs maintained sealed contact with the bioreactor fittings via their internal 
elasticity.  Previous work (39) has indicated that fetal pulsatile conditioning enhance 
blood vessel formation; therefore, conditions resembling those of human late gestation 
with mean pressures of ~50mmHg, amplitudes of ~20mmHg and 140-180 beats per 
minute (bpm) were chosen (93, 94). 
 
 
 
 
Figure 2.4:  Representative 
sinusoidal waveform for bioreactor 
experiments.  Amplitutde and 
frequency mimic those of late 
human gestation (88) 
 
  
To measure system pressures, in-line pressure transducers (one per chamber) 
were introduced.  Media flow then returned to the reservoir.  This system setup allows 
for systematic, concurrent control over all parameters including flow rate, pulse 
frequency, overall pressure and pressure amplitude.  All system components, except for 
presterilized pressure transducers, were autoclaved and assembled in a sterile, laminar 
flow hood. 
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2.6.1 Bioreactor I 
 
 This experiment consisted of two bioreactors, with six constructs containing both 
the SMC and EC layer and six constructs containing only an SMC layer.  In each 
bioreactor, three constructs were mechanically conditioned and three were kept under 
static conditions.  Constructs from this experiment will further be denoted as EC+/dyn+ 
for dynamic constructs with an EC layer, EC-/dyn+ for dynamic constructs without an 
EC layer, EC+/dyn- for static constructs with an EC layer, and EC-/dyn- for static 
constructs without an EC layer.  For the first three days of experimentation, the flow rate 
was increased to 360 Ml/min (120 Ml/min per construct) in 40 Ml/min increments, while 
mean pressures increased to ~50mmHg.  On day 4, pulsation was introduced yielding an 
average waveform of 60/40mmHg at a frequency of ~160bpm to achieve the late human 
gestation conditions.  Media was changed every 2-3 days to replenish nutrients, stabilize 
Ph and prevent contamination.  The bioreactors were run for a total period of 21 days, 
after which samples were harvested for analysis. 
 
2.6.2 Bioreactor II 
 
 Three construct types were utilized in this experiment.  The first set contained all 
three cell types (EC, SMC, fibroblast), the second set contained the EC and SMC layers, 
and the third set contained only the SMC layer.  All constructs were run under dynamic 
conditions and the following nomenclature will be used to refer to the different 
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constructs for discussion: Fib+/EC+, Fib-/EC+, Fib-/EC-.  Reactor 1 contained Fib-/EC- 
constructs, reactor 2 contained Fib+/EC+ constructs and reactor 3 contained Fib-/EC+ 
constructs.  The experiment was run for a total period of 18 days.  Over the first five 
days, the overall flow rate was slowly increased to 360 Ml/min (120 Ml/min per 
construct) in ~40Ml/min increments.  Pulsation was introduced on day 4.  After 
achieving full flow, the average waveforms were 128/100, 120/90 and 120/90 mmHg for 
reactors 1, 2 and 3, respectively, with a pulsation frequency of ~160bpm.  Media was 
changed every 2-3 days to replenish nutrients, stabilize Ph and prevent contamination.  
After the experiment’s completion, samples were harvested for analysis. 
 
2.6.3 Bioreactor III 
 
 This experiment was performed with three constructs run under dynamic 
mechanical conditioning and three constructs left under static conditions.  Media was 
changed every 2-3 days to replenish nutrients, stabilize pH and prevent contamination.  
The system was run for a total period of 15 days.  For the first 7 days, flow was slowly 
and systematically ramped from 60 Ml/min to a final flow rate of 360 Ml/min, yielding 
an average flow of 120 Ml/min per construct.  Pulsation was introduced at day 4, and the 
average waveform was 65/40mmHg with ~160bpm when full flow was achieved on day 
9.  After 15 days, samples were collected from both dynamic and static constructs, which 
will be denoted as dyn+ and dyn- for results discussion. 
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2.7 Sample Collection 
 
2.7.1 Vocal Fold Experiment 
 
 After the duration of the experimental run, samples were collected by taking 
circular rings with a sterile 8mm punch.  Samples were briefly washed in PBS with 1% 
PSA.  Half of the samples were then placed in sterile 1.5Ml tubes, frozen by liquid N2 
and stored at -80°C until analysis.  The other half were taken for mechanical testing and 
subsequently stored at -80°C for further analysis. 
 
2.7.2 Bioreactor Experiments 
 
 After completion of each experimental run, samples were collected in the 
following manner.  Each construct was cut into ~6 cylindrical segments at ~4-6mm in 
length.  The ends of each construct were discarded.  For bioreactors II and III, the inner 
luminal layer was removed to avoid interference of the ECs in sample analysis.  Samples 
allocated for Qrt-PCR and western blot assays were immediately transferred to RNA-
later (Ambion) to preserve RNA.  These samples were then stored at 4°C overnight and 
subsequently transferred to -80°C.  The remaining segments for each construct were 
washed with PBS for immediate mechanical testing and later histological analysis. 
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2.7.3 PDMSstar-PEG Hydrogels 
 
 Following the experimental run, gels were transferred to PBS and cut into 6 
segments.  End sections were used for mechanical analysis.  One section from each was 
transferred to a 1.5Ml tube, frozen immediately in liquid N2 and stored at -80°C.  One 
section from each was cut and transferred immediately to RNA-later, stored at 4°C 
overnight and transferred to -80°C.  Samples taken for histological analysis were 
transferred to Tissue Tek culture media (Sakura Finetek), stored at 4°C overnight and 
transferred to -20°C until use.  Mechanical testing samples were then taken for 
immediate analysis on an Instron 3342 mechanical testing device. 
 
2.8 Mechanical Testing 
 
 All samples were analyzed on an Instron 3342 mechanical testing device 
equipped with a 10N load cell. 
 
2.8.1 Vocal Fold Experiment 
 
 Samples with dimensions of 8mm diameter and 0.55mm thickness were tested 
under compression to determine elastic modulus. 
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2.8.2 TEVG Experiments 
 
 Samples for TEVG experiments were tested under tension to determine elastic 
modulus.  The technique used was an application of the circumferential property testing 
developed and validated for accuracy in previous works (95, 96).  This technique 
approximates the area of force application on the ring segments as two rectanges, with 
sides equal to the width and wall thickness of the ring (measured by calipers).  The 
gauge length, lgauge, was calculated as the diameter of the ring at half wall thickness.  
Strain was then determined by the equation ∆l/lgauge (eq1) and the modulus was 
calculated by the stress-strain output from the testing device after applying a uniaxial 
strain rate of 6mm/min.  Figures 2.5 and 2.6 show example output graphs of Bioreactor 
III, with the stress range of interest taken to be 10-25 kPa.  The measured elastic moduli 
could then be used to estimate the transmural strain experienced by the grafts under 
mechanical conditioning in the bioreactor.  The following equation adapted from the 
Bernoulli equation: 
Eh
rP
v
v∆=ε (eq2), where ε = strain, ∆P = peak-to-trough pressure rise, E 
= elastic modulus, rv = vessel inner radius, and  hv = vessel wall thickness (97).  This 
method has been successfully applied to estimate circumferential strains experienced by 
PEG hydrogel in previous works (41).  Wall shear stress was estimated by the Hagen-
Poiseuille equation (98): 
4
8
r
LQ
P
π
µ
=∆ (eq3), where ∆P = pressure drop, L = length of 
pipe, µ = dynamic viscosity, Q = volumetric flow rate, and r = radius. 
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Figure 2.5:  Stress/strain curve for approximation of TEVG elastic modulus 
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Figure 2.6:  Stress/strain interval from 10-25kPa for estimation of TEVG elastic 
modulus 
 
41 
2.9 Biochemical Analysis 
 
 Samples used for biochemical analysis had previously been snap frozen in liquid 
N2 and stored at -80°C until use.  For every test performed, standards were also 
encapsulated in equivalent PEGDA hydrogels and digested before analysis to account 
for any differences that hydrogel encapsulation may introduce. 
 
2.9.1 DNA Analysis 
 
 DNA analyses were performed as an assessment of the number of cells present 
upon experimental completion.  This gives an assessment of overall cell viability inside 
the hydrogels.  Samples from the hydrogels were thawed, weighed, digested in 10N 
NaOH and neutralized.  The DNA content of each sample was then determined using the 
PicoGreen assay (Invitrogen).  A conversion factor of 6.6pg DNA/cell was used to 
convert resultant DNA content to total cell number with calf thymus DNA (Sigma) used 
as a standard (41). 
 
2.9.2 Sulfated GAG Anlaysis (sGAG) 
 
 The Blyscan assay (Biocolor) was used to measure the total sGAG production.  
80Μl of each sample (digested by 10N NaOH) were neutralized and combined with 
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120Μl Blyscan dye reagent.  Immediately following addition of the dye, the absorbance 
at 525nm was measured and quantified in relation to CSC-B (Sigma) as a standard. 
 
2.9.3 Collagen Analysis 
 
 Collagen production was estimated by hydroxyproline levels within the hydrogel 
samples.  Samples were hydrolyzed for 18h at 110°C in 6N HCl and subsequently dried 
by centrivap (Labconco).  After completion of the drying step, samples were 
resuspended in DI H2O and was reacted with chloramine T and p-dimethylbenzaldehyde 
as previously described (99).  L-4-hydroxyproline was used as a standard, and samples 
were read at 550nm and quantified relative to the standard.  The total collagen content 
was then obtained by dividing total hydroxyproline by 0.13. 
 
2.9.4 Elastin Analysis 
 
 As described in previous work, elastin levels were determined by a ninhydrin 
assay (100).  Following digestion at 100°C in 10N NaOH, samples were pelleted and 
further digested in 6N HCl at 110°C for 18h and subsequently dried by centrivap.  The 
remaining amino acids were boiled in the ninhydrin reagent, cooled and read at 570nm 
(41), and quantified using α-elastin (MP Biochemicals) as a standard.  In addition to the 
ninhydrin assay, direct ELISA can also be used to analyze cellular elastin production.  
Sample digestion was accomplished with 0.1M NaOH for 24h at 37°C.  Samples were 
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then neutralized and further digested with 0.25M oxalic acid at 100°C overnight.  
Microcon YM-3 centrifugal filters (Millipore) were used to exchange oxalic acid for 
PBS.  Following exchange, 100µL of each sample were added to a high binding EIA 96 
well plate (Nunc) for 3h at RT.  The primary elastin antibody (clone B4) was applied 
followed by donkey anti-mouse HRP secondary antibody and 2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (Sigma).  Samples were analyzed at 410nm and 
quantified relative to bovine aortic elastin (Sigma) as a standard. 
 
2.10 Histological Analysis 
 
 All samples assigned for histological analysis were frozen in Tissue-Tek media 
(Sakura Finetek) before cutting on a Jung CM 1800 cryogenic cutting device 
(Histotronix) at 35µm thickness.  Samples were first fixed with 10% formalin for 10min 
followed by Peroxidaze (Biocare Medical) treatment for 10min.  Sections were then 
blocked with Terminator (Biocare Medical) for 10 min and then exposed to the primary 
antibody for 1h.  The secondary antibody was then applied for 30min followed by 
application of a detection kit.  Table 2.4 shows the primary antibodies with their 
respective concentrations in HBS.  Table 2.5 shows the different secondary antibodies 
used and their corresponding detection kits.   
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Table 2.4:  List of antibodies used in histological staining, RT-PCR 
and Western blotting with antibody type, source and staining dilution 
Antibody Type  Source 
Satining 
Dilution 
Collagen I Rabbit IgG Rockland 1:20 
Collagen II Rabbit IgG Rockland 1:20 
Collagen III Rabbit IgG Rockland 1:20 
Elastin (BA-4) Mouse IgG Santa Cruz 1:20 
Myo-d (c20) Rabbit IgG Santa Cruz 1:20 
GAPDH (V18) Goat IgG Santa Cruz N/A 
SM α-actin (1A4) Mouse IgG Santa Cruz 1:20 
SM γ-actin (B4) Mouse IgG Santa Cruz 1:20 
Osteocalcein (fl-95) Rabbit IgG Santa Cruz 1:20 
SRF (G-20) Rabbit IgG Santa Cruz 1:20 
Myocardin (h300) Rabbit IgG Santa Cruz 1:20 
Elk-1 (i-20) Rabbit IgG Santa Cruz 1:20 
Calponin (N-15) Goat IgG Santa Cruz 1:20 
Fibrillin (c-19) Goat IgG Santa Cruz 1:20 
c-Fos (4) Rabbit IgG Santa Cruz 1:20 
c-Jun (h79) Rabbit IgG Santa Cruz 1:20 
p-elk-1 (B4) Mouse IgG Santa Cruz 1:20 
CD-34 (C-18) Goat IgG Santa Cruz 1:20 
Sk/cd α-actin (5c5) Mouse IgG Santa Cruz 1:4 
PCNA (pc10) Mouse IgG Zymed 1:20 
PKC (A-3) Mouse IgG Santa Cruz 1:20 
pERK  Mouse IgG Santa Cruz 1:20 
   
 
Table 2.5:  Secondary antibodies used in histological staining, RT-PCR and Western blotting with 
secondary anti-body type, source, staining dilution, detection kit and positive detection stain 
Secondary Antibody Source Staining Dilution 
Detection 
Kit Stain 
Universal Link IgG Biocare N/A 4+ HRP Chromogen AEC 
Donkey anti-mouse IgG HRP Santa Cruz 1:20 4+ HRP Chromogen AEC 
Donkey anti-mouse IgG AP Santa Cruz 1:20 N/A 
Chromogen Ferangi 
Blue 
Donkey anti-rabbit IgG-AP Santa Cruz 1:20 N/A 
Chromogen Ferangi 
Blue 
Donkey anti-rabbit IgG-HRP Santa Cruz 1:20 4+ HRP Chromogen AEC 
Goat anti-mouse IgM-HRP  Santa Cruz 1:20 4+ HRP Chromogen AEC 
Donkey anti mouse AP Jackson 1:50 N/A 
Chromogen Ferangi 
Blue 
Donkey anti rabbit AP Jackson 1:50 N/A 
Chromogen Ferangi 
Blue 
Donkey anti mouse HRP Jackson 1:50 4+ HRP Chromogen AEC 
Donkey anti rabbit HRP Jackson 1:50 4+ HRP Chromogen AEC 
Donkey anti goat HRP Jackson 1:50 4+ HRP Chromogen AEC 
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Histological stainings for elk1, myocardin and AFABP required exposure to a 
buffer solution (100Mm NaCl, 300Mm sucrose, 3Mm MgCl2, 10Mm HEPES, 0.5% 
Triton-100X) prior to application of the primary antibody.  Stained sections were then 
observed both qualitatively and quantitatively through an Axiovert microscope (Zeiss).  
To quantify the results, the total number of cells was compared to the total number of 
positively stained cells for each individual staining. 
 
2.11 RNA Isolation 
 
 Samples were stored at -80°C in RNA-later until use.  They were transferred to 
2Ml screw-cap microfuge tubes containing 1.5Ml of Trizol reagent and 1Ml of 3.2mm 
diameter stainless steel beads.  Homogenization was accomplished through cycling the 
tubes at 4800rpms in 10s cycles followed cooling on ice.  The tubes were then 
centrifuged and the supernatants collected and mixed with chloroform (Sigma), shaken 
for 15s and centrifuged again.   
The aqueous phase from each tube was separated from the phenol-chloroform phase, 
which was extracted and stored at -20°C for later protein isolation.  Isopropanol, with 
Rnase-free glycogen as a carrier, was used to precipitate the RNA.  The RNA pellet was 
washed with 75% and then 95% ethanol and subsequently exposed to Dnase (Qiagen) at 
37°C for 30min.  The mixture was then held at 70°C for 5min to inactivate the Dnase, 
then cooled on ice.  RNA was again precipitated by 10Μl of 3M sodium acetate (Ph 5.5) 
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followed by 275Μl of 100% ethanol per 100Μl of mixture.  The pellet was again 
washed each with 75% then 95% ethanol and resuspended in 51Μl of Rnase-free water. 
 
2.12 qRT-PCR 
 
 Superarray provided the proprietary Qrt-PCR primers for rat myocardin, calponin 
h1 and GAPDH, and efficiencies of ~1 were verified.  Each sample was measured with a 
Biorad i-Cycler detection system (Biorad) and the SuperScript III Platinum One-Step 
Qrt-PCR kit (Invitrogen).  6 Μl of template and 5Μl of primer were added per 25Μl of 
reaction mixture.  SYBR Green fluorescence was used as a basis for monitoring the 
amplification during the PCR phase with a threshold value for exponential phase of 
amplification determined using MyiQ software (Biorad).  The threshold was marked and 
used to determine the Ct or amplification cycle for each sample.  For the constructs the 
following equation was used to quantify gene expression levels relative to the 
housekeeping gene GAPDH: 2-∆Ct,gene=2-(Ct,gene-Ct,GAPDH).  The average 2-∆Ct,gene for the 
EC-/dyn+ constructs was used to normalize the other groups’ 2-∆Ct,gene averages.  Results 
were verified by melting curve analysis and agarose gel elctrophoresis. 
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2.13 Western Blotting 
 
2.13.1 Protein Isolation 
 
 Protein isolation was conducted by the method set forth in previous work (101). 
The phenol-chloroform phase from the RNA extraction procedure was mixed with 
ethanol to precipitate the remaining DNA.  The liquid phases were dialyzed in 3.4kDa 
SnakeSkin dialysis membranes (Pierce) for 60h at 4°C against aqueous 0.1% sodium 
dodecyl sulfate (SDS) while changing the buffer solution every 18-20h.  A tri-phase 
mixture resulted, yielding a globular mass as the phase of interest.  This phase was 
collected and resuspended in PBS with 0.5% SDS and 1% Triton X-100. 
 
2.13.2 Blotting Procedure 
 
 A 10% SDS-PAGE gel was used to separate 10µg of total protein per sample at 
180V for 1h, which were then transferred to nitrocellulose membranes (Pierce) at 25V 
for 1.5h.  The membrane was blocked with TBS-BSA (Tris-buffered saline and 3 wt% 
bovine serum albumin) and primary antibodies were diluted in the same buffer and 
applied overnight at 4°C with constant rotation.  The primary antibodies were detected 
with donkey anti-mouse-IgG-HRP or donkey anti-rabbit-IgG-HRP (Jackson 
Immunoresearch) with subsequent application of luminal chemiluminescent reagent 
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(SCBT).  The signal was detected using Kodak X-Omat LS Film (Kodak) (88).  Table 
2.5 shows the proteins detected and the corresponding primary antibodies used. 
 
2.13.3 Semi-quantitative Procedure 
  
 To quantitatively assess the results of the blotting, intensities of developed films 
were detected with a high-resolution optical scanner (Dell).  Each protein band was 
analyzed for optical density using the GelPlot2 Macro of Scion Image software (Scion).  
For elastin, the primary antibody chosen recognizes mature elastin as well as three iso-
forms of tropoelastin, yielding separate bands for the different proteins.  The tropoelastin 
bands were ignored and only the mature elastin was analyzed for comparison between 
constructs.  GAPDH was used as a normalizing basis, and each protein band density was 
divided by its corresponding GAPDH band.   
 
2.14 Statistical Analysis 
 
 Data are reported with a mean and corresponding standard deviation.  
Comparisons between samples were accomplished through the use of ANOVA and 
Tukey’s post hoc test (SPSS).  A p < 0.05 was taken as the basis for statistical 
significance.   
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CHAPTER III 
VOCAL FOLD EXPERIMENT 
 
3.1 Introduction 
 
 ECM components have received increasing recognition of their importance in 
cell behavior and function.  They have been shown to influence several areas including 
osmosis, cell migration, differentiation, molecular transport and molecular concentration 
(102, 103).  The ECM consists of traditional structural support components such as 
collagen and elastin, as well as interstitial components composed primarily of glycans 
and proteoglycans, or GAGs.  HA has been widely studied and is considered one of the 
most important GAGs in terms of influencing cells of the vocal fold, especially in 
functions such as wound healing (102, 103).  Other GAGs that may also prove to be 
influential over vocal fold cell behavior, such as CSC, DS and HS, have not been as 
widely studied.  This work seeks to increase understanding of the effects of different 
proteoglycans on vocal fold cells, specifically PVFfs.  PVFfs were chosen as bovine 
cells have been used widely as a human model in tissue engineering (99, 104). 
 Vocal fold fibroblasts interact with ECM proteoglycans through surface 
receptors.  The most common surface receptor identified in vocal fold tissue is CD44, 
and it has been identified as a primary surface protein in fibroblasts, hematopoietic cells 
and tumor cells (105-108).  CD44 has been widely studied in its relation as a surface 
receptor for HA, but has also received recognition as a significant surface receptor for 
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DS, HS and CSC as well (108-112).  In addition, CD44 in VFfs is responsible for 
controlling the extracellular signal-related kinase (ERK) and protein kinase C (PKC) 
transcription pathways, important for the regulation of VFfs.  The work presented here 
seeks to expand understanding of GAG influence over VFf behavior and function.  PVFf 
were encapsulated in 10kDa PEGDA and studied for potential effects of GAG presence 
over the ERK and PKC transcription pathways and their control over ECM deposition. 
 
3.2 Experimental 
 
A brief experimental will be presented here.  For a more detailed description, see 
the relevant methods sections in Chapter II.  Hydrogel precursor solutions were prepared 
with 0.1g/mL 10kDa PEGDA and 1µmol/mol ACRYL-PEG-RGDS in HBS (10mM 
HEPES, 150mM NaCl, pH 7.4) and sterilized by filtration (75).  With this procedure, 
four precursor solutions were prepared, and to one precursor solution each, CSC, HA, 
HS and DS were added at 1mg/mL.  In addition, 10µL/mL of a 300 mg/mL solution of 
acetophenone (Sigma) dissolved in N-vinylpyrrolidone (Sigma) were added to each 
solution.  PVFfs at passage 8-10 were washed with phosphate buffered saline (PBS), 
harvested and suspended at 1.6x106 cells/mL in the hydrogel precursor solutions.  
Precursor solutions were then loaded into a flat plate geometry with a thickness of 
1.1mm and photopolymerized under UV light (365 nm, ~10 m mW/cm2, UVP model B-
100SP, Upland) for 2 mins (1min/side).  The hydrogel were transferred to Omnitrays 
(Nunc) fitted with 4 sterile polycarbonate bars to simultaneously prevent gel flotation 
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and prevent gel contact with the tray bottom.  Gels were immersed in DMEM 
supplemented with 10% BCS, 100 µU/mL penicillin, and 100 mg/L streptomycin and 
maintained at 37 ºC/5% CO2 for a period of 17 days.  Media was changed every two 
days until samples were harvested for analysis. 
After the duration of the experimental run, samples were collected by taking 
circular rings with a sterile 8mm punch.  Samples were briefly washed in PBS with 1% 
PSA.  Half of the samples were then placed in sterile 1.5Ml tubes, frozen by liquid N2 
and stored at -80°C until analysis.  The other half were taken for mechanical testing and 
subsequently stored at -80°C for further analysis.  Samples were analyzed for 
mechanical properties immediately following sample collection.  ECM analysis included 
collagen I, III and elastin.  Collagen types I and III are the primary collagen components 
of the vocal folds.  Total collagen was determined via the hydroxyproline assay, while 
individual collagen types were determined by histological staining with quantitative cell 
counting.  Elastin production was analyzed through direct ELISA.  Histological stainings 
were also performed and quantified for SMα-actin, an indication of vocal fold scarring, 
proliferating cell nuclear antigen (PCNA), a cell-proliferation marker, pERK and PKC. 
 
3.3 Results and Discussion 
 
 Figure 3.1 shows the results of scaffold mechanical testing.  From the figure, it is 
clear that the mechanical properties of the DS gels differ significantly from the other 
formulations.  Scaffold physical properties have significant influence over cell behavior.  
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Since the goal of this experiment was to study GAG influence, and for the DS 
formulation, the mechanical properties cannot be decoupled from other influential 
components, results from this formulation will be ignored in the experimental analysis. 
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Figure 3.1:  Mechanical properties for individual PEGDA formulations modified with selected 
GAGs.  The DS formulation shows significant deviation from the other three formulations, and 
thus will not be included in the experimental analysis 
 
 
 Figures 3.2 and 3.3 show the total collagen production (biochemical analysis), 
collagen I and collagen III (histological staining), respectively.  While total collagen 
production is consistent, it can be seen from Figure 3.3 that the individual collagen types 
differ significantly between formulations.  Collagen I production was enriched in CSC 
and HS gels (HS enrichment not statistically significant), while collagen III was enriched 
in HA gels.  In natural vocal fold tissue, the ratio between collagen I and III production 
is approximately 1, indicating some effect of the HS and CSC proteoglycans on the 
fibroblast signaling process. 
* 
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Figure 3.2:  Total collagen production by hydroxyproline assay.  No 
significant different exists between selected formulations 
 
 
Figure 3.3:  Collagen I and III production quantified by histological 
staining and cell counting.  *Significant difference between HA and 
CSC formulations.  **Significant difference between HA and HS 
formulations 
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 Figure 3.4 contains elastin production data obtained from direct ELISA.  No 
significant differences exist between the formulations, indicating the proteoglycans do 
not affect VFf elastin production. 
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Figure 3.4:  Elastin production as measured by direct ELISA 
 
  
 Figures 3.5 and 3.6 show results for ERK and PKC, respectively.  ERK shows 
significant differences for both CSC and HA from HS, while PKC histological stainings 
showed no significant differences.  This could indicate influence ERK signaling over 
collagen production, but results are not detailed enough to draw comprehensive 
conclusions. 
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Figure 3.5:  ERK expression quantified by histological staining and cell 
counting.  *Significant difference between HS and CSC formulations.  
**Significant difference between HS and HA formulations 
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Figure 3.6:  PKC expression quantified by histological staining and cell 
counting 
 
 
 SM α-actin and PCNA expression results are shown in Figures 3.7 and 3.8, 
respectively and were obtained via histological staining and cell counting.  Results for 
PCNA show no significant difference, but staining for SM α-actin show enhanced levels 
 * 
** 
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in both the HS and CSC formulations.  This trend follows the levels of ERK expression, 
indicating a potential correlation.  High levels of SM α-actin are associated with vocal 
fold scarring and generally present during wound healing.  Increased expression of 
wound healing markers would be expected in replacing damaged tissue, but enhanced 
levels of SM α-actin would be generally undesirable. 
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Figure 3.7:  PCNA expression quantified by histological staining and cell 
counting 
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Figure 3.8:  SM α-actin expression quantified by histological staining and cell 
counting 
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CHAPTER IV 
MECHANICAL CONDITIONING AND EC PRESENCE ON RASMC 
 
4.1 Introduction 
  
 TEVGs have received strong attention in recent years as a potential replacement 
for damaged, small diameter (<6mm) vascular tissue (6, 38-41, 88).  Cell-cell 
interactions as well as mechanical conditioning, including both cyclic strain and shear 
stress, have been shown to have a significant impact on SMC behavior.  Under 
physiological conditions, vascular tissue undergoes constant mechanical stimulation, 
experiencing both cyclic strain and shear stress.  The shear stress experienced by SMCs 
in vivo, however, is an indirect, transmural stress, rather than a direct stress (6, 40, 41).  
They are surrounded by ECM, and are further buffered from direct contact with the 
conditioning fluid by an EC layer.  Few studies mimicking this type of stress and strain 
conditioning have been conducted, and the research presented here seeks to create a 
comprehensive physiological flow system that mimics in vivo conditions and can be 
systematically tuned to give control over pressure waveforms and flow rate.  The system 
setup was shown in Figure 2.2 and is reproduced here.  The individual, decoupled effects 
of mechanical conditioning and EC presence were studied.  Instead of a dry EC 
monolayer, ECs were encapsulated in a thin hydrogel as a separate layer in the 
constructs.  This deviates from natural vascular tissue where ECs are present in a 
monolayer, but facilitates easy removal of the luminal layer for a focused analysis of the 
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SMC layer.  EC+ and EC- constructs were run under both dynamic and static conditions 
and analyzed for SMC phenotype and ECM production. 
 PEG hydrogels were chosen because of their biocompatibility, ease of 
modification and biological “blank slate” nature (25, 113).  The experimental setup 
presented here allows for independent study of the impact of both EC presence as well as 
mechanical conditioning.  This was accomplished through the creation of dual-layered 
hydrogels that mimic the multi-layered structure of natural vascular tissue, with an EC 
monolayer surrounded by an SMC medial layer.  Hydrogels were synthesized through 
photopolymerization of PEG with modified acrylate end groups. 
 
   
 
 
 
 
 
 
 
Figure 2.2:  Physiological flow system to 
control mechanical conditioning in TEVGs.  The 
system consists of a bioreactor chamber to house 
constructs, peristaltic pump to provide flow, and 
a pulsatile pump to provide the sinusoidal 
waveform.  Reactor chamber and media reservoir 
are vented to the atmosphere to maintain 
pressure and allow for gas exchange (41) 
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4.2 Experimental 
 
 A brief experimental will be presented here.  For a more detailed description, see 
the relevant methods sections in Chapter II (Bioreactor I).  A PEGDA precursor solution 
(0.1g/mL 6k PEGDA, 1µmol/mL ACRYL-PEG-RGDS, and 10µL/mL acetophenone in 
HBS-TEOA) was prepared and sterilized by filtration.  RASMCs as passage 9-12 were 
harvested and resuspended at 2x106 cells/mL in the precursor solution and 
photopolymerized in a UV transparent cylindrical mold with an outer diameter of 7.4mm 
and an inner diameter of 5mm (~0.7 mL/construct) for 1 min.  The inner rod was 
removed and replaced with a 4mm glass rod.  For half of the constructs, BAECs at 
passage 9-12 were harvested and resuspended in the precursor solution at 10x106 
cells/mL and added to the cylindrical mold, creating a wall thickness of 1mm.  The 
remaining grafts were completed with an inner layer composed of the precursor solution 
without cells.  The inner layer was photopolymerized for an additional 1min. 
 The dual-layered hydrogels were removed from their molds and briefly rinsed in 
PBS containing 1% PSA.  Constructs were then immersed in DMEM containing 10% 
BCS and 1% PSA and were cultured statically at 37 ºC/5% CO2 for 3 days to ensure 
contamination did not occur.  Media was changed every day until constructs were 
collected for mechanical conditioning. 
 This experiment consisted of two bioreactors and twelve constructs.  In one 
bioreactor, constructs were EC+, with half being run as dyn+ and half being run as dyn-.  
In the remaining bioreactor, constructs were EC-, with half run as dyn+ and half run as 
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dyn-.  For the first three days of experimentation, the flow rate was increased to 360 
Ml/min (120 Ml/min per construct) in 40 Ml/min increments, while mean pressures 
increased to ~50mmHg.  On day 4, pulsation was introduced yielding an average 
waveform of 60/40mmHg at a frequency of ~160bpm to achieve the late human 
gestation conditions.  Media was changed every 2-3 days to replenish nutrients, stabilize 
Ph and prevent contamination.  The bioreactors were run for a total period of 21 days, 
after which samples were harvested for analysis.   
 Constructs were cut into ring segments.  End segments were discarded.  Samples 
for biochemical analysis were snap frozen in liquid N2 and stored at -80°C until use.  
Samples for RNA analysis were diced, transferred to RNA-later, stored at -20°C 
overnight and moved to -80°C until analysis.  Samples designated for histological 
analysis were frozen in Tissue Tek media at -20°C.  Samples for mechanical 
conditioning were rinsed with PBS and immediately tested for elastic modulus.  
Analyses were performed probing both SMC phenotype and ECM production.  
Histological staining was performed for ECM proteins collagen I, III and elastin.  
Staining for differentiation markers myocardin, calponin h1 and elk-1 were also 
performed along with SRF expression.  As an additional measure of differentiation 
marker expression, qRT-PCR was performed for myocardin and calponin h1.  A semi-
quantitative procedure using Western blots was also performed to give further insight 
into collagen I, III, elastin, SRF and elk-1 presence. 
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4.3 Results and Discussion 
 
 Mechanical testing data yielded similar results for all groups of constructs.  
Figure 4.1 shows the average elastic modulus with standard deviation for each 
formulation.  No statistically significant differences were observed.  Applying eq2, 
average circumferential strains of 6% were obtained, with an average pressure amplitude 
of 20 mmHg.  Applying eq3, wall shear stresses were calculated to be ~1 dyn/cm2 in 
dynamic constructs.  The mechanical data obtained allow the effects of mechanical 
conditioning and cell-cell interactions to be decoupled from scaffold physical properties. 
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Figure 4.1:  Mechanical data for all construct formulations.  No 
statistically significant differences were observed 
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Figure 4.2:  Representative immunoblots for differentiation markers 
and ECM deposition (88) 
  
 
 ECM deposition analysis was performed by semi-quantitative Western blotting 
(Figure 4.2) and cell counting of histological staining.  Production of collagen I, III and 
elastin was measured and is presented in Figure 4.3 (88).  Western blots were completed 
and developed over film, which was then optically analyzed for quantitative comparison.  
After optical analysis, average values for each protein were divided by the optical 
density value for GAPDH, chosen as a housekeeping gene.  For comparison between 
immunoblots, films were internally normalized to the average EC-/dyn+ ratio. 
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Figure 4.3:  Quantitative results for ECM deposition.  A)  Western 
blotting results.  B) Histological staining.  *Statistically significant 
difference between EC+/dyn- and EC+/dyn+.  †Significant difference 
between EC+/dyn+ and EC-/dyn-.  ‡ Significant difference between 
EC+/dyn+ and EC-/dyn+.  ##Significant difference between EC+/dyn- 
and EC-/dyn+ (88) 
  
 
 From Figure 4.3A, elastin production increased in EC+/dyn+ constructs relative 
to EC-/dyn- and EC+/dyn- constructs, indicating that mechanical conditioning influences 
elastin deposition.  For collagen I, EC+ constructs showed diminished production.  From 
Figure 4.3B, the trends from the quantitative histology generally agree with those from 
the immunoblotting.  However, standard deviations are too large to draw statistical 
ECM Semi-quantitative Immunoblotting Results 
ECM Histological Cell Counting 
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conclusions.  Combined ECM results indicate different modulation from EC presence 
and mechanical conditioning independently.  Combining EC presence with dynamic 
conditioning reduced collagen I production while enhancing elastin production.  
Previous work has also indicated a reduction in total collagen production with EC+ 
TEVGs undergoing pulsatile conditioning (45).  However, the previous work did not 
isolate diminished collagen production specifically to collagen I.  Ratios between 
collagen I and III in vascular tissue has significant impact on tissue mechanical 
properties, with enriched collagen III tissues identified as more elastic (114).  Further 
work must be done to investigate the underlying signaling pathways controlling collagen 
production to attempt to block any collagen I reduction.  While the decoupled effects of 
mechanical conditioning in EC- constructs did not show significant increase in ECM 
production, this is likely do to a limited sample number, and reducing standard 
deviations may bring results into line with previous work (40, 57, 60, 115, 116). 
 Figure 4.4 (88) shows quantitative results for SRF, elk-1, myocardin and 
calponin.  SRF and elk-1 were analyzed via Western blots and histological staining.  
Myocardin and calponin h1 were analyzed via qRT-PCR and histological staining.  EC 
presence and mechanical presence independently enhanced SRF expression.  
Specifically, EC+/dyn+ constructs showed greater SRF expression relative all other 
formulations. 
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Figure 4.4:  Quantitative results for SRF, elk-1, myocardin and calponin h1.  A) SRF and elk-1 quantified 
by Western blot.  B) SRF and elk-1 quantified by histological staining.  C) Myocardin and calponin h1 
quantified by qRT-PCR.  D) Myocardin and calponin h1quantified by histological staining.  *Significant 
difference between EC+/dyn- and EC+/dyn+ constructs.  **Significant difference between EC-/dyn- and 
EC-/dyn+ constructs.  †Significant difference between EC+/dyn+ and EC-/dyn- constructs.  ‡Significant 
difference between EC+/dyn+ and EC-/dyn+ constructs.  ##Significant difference between EC+/dyn- and 
EC-/dyn+ constructs (88) 
 
 
 Analysis for elk-1 by immunoblot showed no statistically significant differences.  
SRF analysis by histology showed enhanced expression in EC+/dyn+ over EC+/dyn- 
constructs, indicating an influence of mechanical conditioning over expression of this 
transcription factor.  Elk-1 analysis by histology showed similar enhancement in 
EC+/dyn+ constructs.  Overall, these results agree with the trends observed through 
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Western blots.  Figure 4.5 (88) shows representative histological staining for each 
construct type for collagen I, III, elastin and calponin h1. 
 qRT-PCR for calponin h1 showed enhanced expression in dyn+ constructs over 
dyn- constructs.  Calponin h1 was also enhanced most effectively in EC+/dyn+ 
constructs.  Myocardin expression was enhanced in EC+/dyn+ constructs relative to the 
EC-/dyn- constructs.  Histological staining results agreed in general with those obtained 
through gene expression.  Calponin expression was enhanced in EC+/dyn+ relative to 
EC+/dyn- constructs, while EC+/dyn+ constructs were significantly enhanced over all 
other formulations.  These combined results indicate that both EC presence and 
mechanical conditioning enhance SMC differentiation.  Myocardin promotes calponin 
h1 expression, which preferentially drives SMC differentiation, while elk-1 competes 
with myocardin as an SRF binding partner and promotes proliferation (48-50, 62).  
Therefore, it can be expected that an increase in the myocardin:elk-1 ratio would 
enhance calponin h1 expression.  These results are in agreement with previous work (56, 
117). 
 Immunostaining was also performed for traditional EC markers, vWF and NOS.  
The results showed localized production of each to the luminal layer, indicating minimal 
to no cell migration between layers.  Representative images of these stainings can be 
seen in Figure 4.6 (88).  The localization of the EC layer is important, because it allows 
for conclusions for SMCs in the medial layer to be drawn without interference from EC-
produced proteins. 
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Figure 4.5:  Representative histological staining for collagen I, III, elastin and 
calponin h1.  For collagen I, III and calponin h1, positive staining is red, while for 
elastin, positive staining is blue (88) 
 
 
 
 
Figure 4.6:  Representative images of EC/SMC 
boundary layer.  A) Unstained section of dual-
layered TEVG.  B) Dual-layered construct stained 
for vWF showing localized position of ECs.  C)  
EC section stained for NOS to show EC 
functionality.  Positive stainings are black (88) 
Layer junction  
A 
B C 
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CHAPTER V 
MECHANICAL CONDITIONING, EC AND FIBROBLAST PRESENCE ON 
MSCs 
 
5.1 Introduction 
  
 This experiment expands on the results obtained in previous bioreactor 
experiments by introducing the adventitial, or fibroblast layer of vascular tissue into the 
TEVGs.  Additionally, RASMCs will be replaced by 10T1/2 mesenchymal stem cells.  
Mesenchymal stem cells are undifferentiated progenitor cells capable of maturing into 
several different lines including myocytes, chondrocytes, adipocytes, osteoblasts and 
SMCs (63-65).  They are an attractive option for TEVGs because they are available from 
multiple sources throughout the potential patient’s own body, eliminating the need for 
the introduction of a foreign cell line into the body, thus minimizing risk of rejection and 
inflammatory response.  Similar factors affecting SMC phenotype and ECM production, 
including mechanical conditioning and inter-cell communication, have also been shown 
to influence mesenchymal stem cells (66-68).  Progenitor cells have also shown greater 
consistency in behavior over primary cells regardless of their source, and are well 
characterized (89-92).  This experiment will attempt to decouple the effects of the 
adventitial layer on SMC behavior from mechanical conditioning.  One additional 
change was the thickness of the EC layer, which has been reduced from 1mm to 0.5mm 
to more closely resemble the monolayer of natural vascular tissue. 
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5.2 Experimental 
 
 A brief experimental will be presented here.  For a more detailed description, see 
the relevant methods sections in Chapter II (Bioreactor II).  A PEGDA precursor 
solution (0.1g/mL 6k PEGDA, 1µmol/mL ACRYL-PEG-RGDS, and 10µL/mL 
acetophenone in HBS-TEOA) was prepared and sterilized by filtration.  3T3 fibroblasts 
at passage 14-16 were harvested and resuspended at 8.6x106 cells/mL in the precursor 
solution.  The solution (0.65mL/construct) was then added to a UV transparent 
cylindrical mold with an inner glass rod of diameter 6.9mm and an outer plastic tube of 
diameter 7.4mm for 1/3 of constructs.  The solution was photopolymerized under 
longwave UV for 1min.  The inner rod was removed and replaced by a rod of diameter 
4.5mm.   
 10T1/2 mesenchymal stem cells at passage 18-21 were harvested and 
resuspended at a concentration of 10x106 cells/mL in the precursor solution.  The 
solution (0.55mL/gel) was then added to the cylindrical mold and photopolymerized for 
an additional 1min.  The inner rod was removed and replaced by a rod of 4mm.  BAECs 
as passage 9-12 were harvested and resuspended at 7x106 cells/mL in the precursor 
solution.  The solution was then added to the mold and photopolymerized for an 
additional 1min.  For another 1/3 of constructs, the fibroblast layer was replaced by 
blank PEGDA precursor solution and was prepared with a 10T1/2 layer and a BAEC 
layer.  For the final 1/3 of constructs, the fibroblast and BAEC layers were replaced with 
blank PEGDA precursor solution, leaving only the medial 10T1/2 layer.  The tri-layered 
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hydrogels were removed from their molds and briefly rinsed in PBS containing 1% PSA.  
Constructs were then immersed in DMEM containing 10% BCS and 1% PSA and were 
cultured statically at 37 ºC/5% CO2 for 3 days to ensure contamination did not occur.  
Media was changed every day until constructs were collected for mechanical 
conditioning. 
 A three reactor system was used in this experiment to accommodate the three 
construct types.  Reactor 1 contained fib-/EC- constructs, reactor 2 contained fib+/EC+ 
constructs and reactor 3 contained fib-/EC+ constructs.  The experiment was run for a 
total period of 18 days.  Over the first five days, the overall flow rate was slowly 
increased to 360 Ml/min (120 Ml/min per construct) in ~40Ml/min increments.  
Pulsation was introduced on day 4.  After achieving full flow, the average waveforms 
were 128/100, 120/90 and 120/90 mmHg for reactors 1, 2 and 3, respectively, with a 
pulsation frequency of ~160bpm.  Media was changed every 2-3 days to replenish 
nutrients, stabilize Ph and prevent contamination.  After the experiment’s completion, 
samples were harvested for analysis.  Constructs were cut into ring segments.  End 
segments were discarded.  Samples designated for histological analysis were frozen in 
Tissue Tek media at -20°C.  Samples for mechanical conditioning were rinsed with PBS 
and immediately tested for elastic modulus.   
 
5.3 Results and Discussion 
 
 Mechanical testing results are shown in Figure 5.1.  No significant difference 
exists between constructs.  This allows for the elastic modulus to be removed as an 
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experimental variable.  Figures 5.2 and 5.3 show quantitative histological staining results 
for collagen and elastin deposition, respectively.  Standard deviations are too high to 
make statistical conclusions, but some general trends can be observed. 
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Figure 5.1:  Construct elastic moduli.  No statistically significant differences were 
observed 
 
  
   Deposition of collagen I and III were similar on average.  This is in contrast to 
the previous experiment which showed a decrease in collagen I production with EC 
presence.  Collagen II is indicative of a chondrocyte phenotype.  Collagen II was overall 
diminished by presence of EC and fibroblasts, and further reduced by dynamic 
conditioning.  This indicates that physiological conditions inhibit 10T1/2 cells from 
differentiating towards a chondrocyte phenotype.  
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Figure 5.2:  Collagen deposition by quantitative histological staining 
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Figure 5.3:  Elastin deposition by quantitative histological staining 
 
 Elastin was slightly elevated on average by the presence of ECs, but differences 
are not statistically significant.  This is in agreement with previous experiments.  Figure 
5.4 shows the important differentiation markers for SMC development.  Myocardin 
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directly regulates calponin h1 expression, and this trend is generally followed in the 
results.  Contrary to experiments performed with mature SMCs, EC presence diminished 
both myocardin and calponin h1 expression.  Standard deviations are too large to draw 
conclusions for SRF and elk-1, but elk-1 expression appears reduced with EC presence, 
also contrary to previous results.  EC presence slightly elevated elk-1 expression, but 
was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4:  SMC differentiation marker expression by quantitative histological 
staining 
 
 
 Mesenchymal stem cells have the ability to differentiate into a variety of cell 
lines including SMCs, osteoblasts, chondrocytes, adipocytes and myocytes.  Osteoblasts 
are present in bone tissue, chondrocytes are found in cartilage, adipocytes in fat tissue 
and myocytes in cardiac muscle.  Each has different characteristic markers that can be 
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identified to test for preferential differentiation.  For SMCs, osteoblasts, chondrocytes, 
adipocytes and myocytes, these markers are calponin h1, osteocalcein, collagen II, 
AFABP and skeletal cardiac α-actin (sk/cd α-actin), respectively.  These markers (except 
collagen II and calponin h1) are shown in Figure 5.5.  In general, dynamic conditioning 
and EC presence reduced expression of adipocyte, and myocyte phenotypes, in addition 
to chondrocytes as noted before. 
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Figure 5.5:  Mesenchymal stem cell differentiation markers from quantitative histological 
staining 
  
 To gain further insight into the SMC differentiation pathway via SRF, samples 
were stained for sp-1, SM α-actin, c-fos and c-jun.  SM α-actin, like calponin h1, is a late 
term differentiation marker for SMCs.  As noted before, pelk-1 competes with 
myocardin as an SRF binding partner and favors proliferation over differentiation.  
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Binding of pelk-1 results in c-fos expression.  In addition, c-jun pairs with c-fos in this 
signaling pathway.  Taken together, these results give more information into which 
pathway the SMCs are favoring and are presented in Figure 5.6.  Binding partners c-jun 
and c-fos were overall enhanced in expression by EC presence.  Sp-1 appeared elevated 
by EC presence, while SM α-actin was slightly reduced.  Taken together, these results 
indicate that the presence of an endothelial layer inhibits the differentiation-favoring 
pathway, while favoring the proliferation pathway. 
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Figure 5.6:  SMC differentiation pathway markers from quantitative histological 
staining 
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CHAPTER VI 
MECHANICAL CONDITIONING AND EC MONOLAYER ON RASMCs 
 
6.1 Introduction 
 
 This experiment seeks to address a potential issue from previous bioreactor 
experiments, namely the 3-dimensional EC configuration.  A technique for applying an 
EC monolayer was developed to more closely mimic the vascular structure seen in vivo.  
Also, mature cell lines were used in an attempt to verify the results from previous 
experiments where a 3-dimensional EC scaffold was used.  MSCs may react differently 
to EC presence than mature SMCs; therefore, the tubular structure must first be 
eliminated as a factor. 
 
6.2 Experimental 
 
A brief experimental will be presented here.  For a more detailed description, see 
the relevant methods sections in Chapter II (Bioreactor III).  The inner layer of the 
TEVGs was prepared with a BAEC (passage 9-12) monolayer at a density of 30x106 
cells/mL.  A precursor solution of 0.1 g/mL PEGDA and 1µmol/mL ACRYL-PEG-
RGDS and 10µL/mL acetophenone in HBS-TEOA was prepared, sterilized by filtration 
and used to resuspend the BAECs.  The solution was then spread on a glass rod (4mm 
diameter) between two Teflon cylindrical molds in a monolayer form and dried under 
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sterile air.  A plastic cylinder of diameter 7.4mm was then added to the cylindrical mold 
to enclose the EC layer.  An equivalent PEGDA precursor solution with resuspended 
SMCs (passage 9-12, 2x106 cells/mL) was then added to the cylindrical mold 
(~0.7mL/construct) and photopolymerized under longwave UV for 2 minutes.  The 
resulting hydrogels were removed from their molds and briefly rinsed in PBS containing 
1% PSA (10 U/mL penicillin, 10 g/L streptomycin, and 10 g/L amphotericin, Mediatech, 
Manassas). Constructs were then immersed in DMEM containing 10% BCS and 1% 
PSA and were cultured statically at 37 ºC/5% CO2 for 3 days to ensure contamination 
did not occur.  Media was changed every day until constructs were collected for 
mechanical conditioning. 
This experiment was performed with three constructs run under dynamic 
mechanical conditioning and three constructs left under static conditions.  Media was 
changed every 2-3 days to replenish nutrients, stabilize pH and prevent contamination.  
The system was run for a total period of 15 days.  For the first 7 days, flow was slowly 
and systematically ramped from 60 Ml/min to a final flow rate of 360 Ml/min, yielding 
an average flow of 120 Ml/min per construct.  Pulsation was introduced at day 4, and the 
average waveform was 65/40mmHg with ~160bpm when full flow was achieved on day 
9.  After 15 days, samples were collected from both dynamic and static constructs, which 
will be denoted as dyn+ and dyn- for results discussion.  Samples were collected by 
cutting ring segments from each construct.  Segments allocated for biochemical analysis 
were snap frozen in liquid N2 and stored at -80°C until use.  Sections designated for 
mechanical testing were rinsed in PBS and immediately tested to avoid any introducing 
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any physical changes to the samples.  Histological sections were frozen in Tissue Tek 
(Sakura Finetek) media overnight at -20°C.   
Histological stainings for calponin h1 and SRF were conducted to test for SMC 
phenotype and maturity.  In addition, ECM markers collagen I and III were stained and 
analyzed.  Biochemical analysis included DNA for determination of cell viability, total 
collagen, elastin and sGAG.  Viability for the EC layer during the experimental run was 
verified by testing for nitrous oxide synthase (NOS) and von Willebrand factor (vWF), 
common EC markers (88, 118).  In addition, a live/dead assay was performed to 
 
6.3 Results and Discussion 
 
 Tensile mechanical testing yielded similar average values for both dyn+ and dyn- 
constructs.  For the dyn+ constructs, the average modulus was 67.5 ± 2.1 kPa, while the 
dyn- construct average was 68.5 ± 4.7 kPa.  Combining the elastic modulus values for 
the dynamic constructs with the applied average ∆P of 20mmHg in eq2 yields an 
average circumferential strain of ~8% experienced by SMCs during in vitro mechanical 
conditioning.  In addition, eq3 yielded a mean wall shear stress of ~1 dyn/cm2. 
 The staining for vWF appear in a localized fashion, indicating the EC luminal 
layer remained intact with minimal to no inter-layer migration of ECs.  NOS in TEVGs 
has been shown to inhibit hyperplasia and maintain SMC homeostasis (119).  Its 
presence here is desirable and expected in dynamic constructs.  Figure 6.1 includes 
representative stainings for these markers.  In addition, Figure 6.1 includes a fluorescent 
image of a live/dead assay as an indicator of cell viability.  Figure 6.1 includes data from 
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24h post fabrication (A-C), 48h of high shear flow conditioning (D-F, I) and prolonged 
low shear flow conditioning (G,H).  Image A is a brightfield image of the fabricated EC 
layer.  Image B is a fluorescent image of a live/dead stain of the same layer and image C 
is a background fluorescent image for comparison to the live/dead image in B.  
Comparison of these two images indicates high cell viability and low cell loss.  Images 
D-F are the same data after 48h of abrupt, high shear conditioning.  Images G and H are 
histological stains for vWF and NOS, respectively after long exposure to low intensity 
shear conditioning.  These images indicate success of the procedure used to form the 
monolayer of these TEVGs and long-term cell viability. 
 Calponin h1 is an indicator of SMC phenotype and is directly regulated by SRF 
(48-50).  These were stained and counted for a semi-quantitative comparison.  This 
information is included in Figure 6.2 along with ECM deposition immunostaining 
including collagen I, III and elastin.  SRF expression was unchanged through dynamic 
conditioning, but calponin h1 expression was significantly enhanced in the dyn+ 
constructs.  This indicates that in vivo dynamic conditioning enhances SMC maturity.  
ECM deposition of elastin was unchanged between dyn+ and dyn- constructs, whereas 
deposition of both collagen I and III was enhanced in dyn+ constructs.  Stainings for 
ECM components also showed pericellularly localized deposition immediately 
surrounding the SMCs, which has been noted in similar work with PEGDA (27, 88). 
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Figure 6.1:  Dual-layer live/dead stainings.  A-C) Images after 24h 
abrupt, high shear conditioning, A) Brightfield image of prepared EC 
monolayer, B) Fluorescent image of live/dead assay on EC layer, C) 
Background fluorescence for comparison to B.  D-F) Images after 
48h slow, low shear conditioning, D) Brightfield image of prepared 
EC monolayer, E) Fluorescent image of live/dead assay on EC layer, 
F) Background fluorescence for comparison to D.  G) Histological 
staining for vWF after prolonged, low shear conditioning.  H) 
Histological staining for NOS after prolonged, low shear 
conditioning.  I) Histological staining for occludin after abrupt, high 
shear conditioning.  Red coloration indicates a positive stain.  Scale 
bars are 40 µm 
 
 
 
Figure 6.2:  Semi-quantitative histological staining results for SMC phenotype 
markers and ECM deposition.  *Significant different between dyn+ and dyn- 
constructs 
SMC Histological Staining 
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 Figure 6.3 shows the localized nature of ECM deposition of SMCs in the 
TEVGs. 
 
 
Figure 6.3:  Histological stainings for SMCs.  A,B) 
Calponin h1 in dyn- and dyn+ constructs, respectively.  
C,D) Collagen I in dyn- and dyn+ constructs, respectively.  
Positive stainings are black.  Scale bar = 40µm 
 
  
 Biochemical analyses were performed to supplement the histological staining 
data for ECM deposition and are shown in Figure 6.4.  Prior to analysis, the EC layer 
was removed from each construct so that all results could be directly applied to the SMC 
layer.  DNA analysis yielded a cell density of ~2x106 cells/g, indicating strong cell 
viability during dynamic conditioning.  Analysis of total collagen showed higher average 
values for dyn+ constructs, but these differences were not statistically significant.  
Results from the other analyses also were not statistically significant.  The combined 
data show an influence of mechanical conditioning on SMC phenotype and behavior, 
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though more samples will be needed to minimize the standard deviations in the 
biochemical analyses. 
 
 
 
Figure 6.4:  Biochemical analysis of SMCs for total collagen, 
elastin and sGAG.  Differences were not statistically significant 
 
 
 A second experiment was conducted with the same setup as the first under which 
constructs were prepared and subjected to high shear conditions (~10 dyn/cm2) over 2 
days.  Similar results for luminal layer viability were obtained with the additional 
expression of occludin, shown in Figure 6.1.  Occludin regulates vascular wall 
permeability, associated with a quiescent EC phenotype (120). 
 
  
  
 
 
Biochemical Analysis of SMCs 
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CHAPTER VII 
PDMSstar-PEG HYDROGELS 
 
7.1 Introduction 
 
 Previous bioreactor experiments sought to investigate the individual and 
combined effects of cell-cell interactions and mechanical conditioning.  Another 
important component for in vitro culture conditions for TEVGs is scaffold physical 
properties, including elastic modulus, water content and surface morphology, mesh size 
and degradation rate.  PEGDA hydrogels have a relatively limited range on the extent of 
mechanical properties than can be achieved.  Incorporation of PDMS into the PEG 
hydrogel network allows for a much wider control over scaffold physical properties, 
spanning both above and below those of native tissue.  Novel PDMSstar materials were 
developed by the Grunlan group for study in TEVGs.  Incorporation of PDMSstar into the 
hydrogel network allows for retention of the non-biofouling nature of pure PEG while 
giving systematic control over elastic modulus, water content and surface morphology 
(70, 71, 73, 74). 
 Preliminary studies by the Hahn and Grunlan groups (72) have shown significant 
control over scaffold modulus and differences in ECM deposition and differentiation 
marker expression on 10T1/2 mesenchymal stem cells.  Changing PDMS content 
changed the cell phenotype that was enriched, suggesting optimization of the scaffold 
physical properties may allow for selective differentiation of mesenchymal stem cells 
84 
toward SMCs.  Initial experiments were conducted with 6kDa PEG combined in 1:99, 
5:95 and 10:90 weight ratios (PDMSstar:PEG) with 1.8kDa, 5kDa and 7kDa MW 
PDMSstar.  This research seeks to expand the formulations tested in order to seek a 
method to fully optimize elastic modulus, water content and surface morphology.  The 
property space being sampled was shown in Figure 1.9.  This work utilizes the TEVG 
synthesis procedure developed during the bioreactor experiments to create cylindrical 
grafts. 
 
7.2 Experimental 
 
 A brief experimental will be presented here.  For a more detailed description, see 
the relevant methods sections in Chapter II.  Formulations selected for synthesis were 
shown in Table 2.3, which is reproduced here.  10T1/2 mesenchymal stem cells at 
passage 21 were harvested and resuspended at a density of 3x106 cells/mL in sterile-
filtered precursor solutions according to Table 2.3 with an overall polymer concentration 
of 10% in HBS-TEOA with 1µmol/Ml ACRYL-PEG-RGDS.  Precursor solutions 
(~0.8mL) were added to UV transparent cylindrical molds with Teflon bases.  The molds 
had an outer diameter of 7.4mm with an inner diameter of 5mm.  Solutions were then 
photopolymerized under longwave UV for a period of 5mins.  The tri-layered hydrogels 
were removed from their molds and briefly rinsed in PBS containing 1% PSA.  
Constructs were then immersed in DMEM containing 10% BCS and 1% PSA and were 
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cultured statically at 37 ºC/5% CO2 for a period of 21 days.  Media was changed every 
two days until samples were harvested for analysis. 
 
Table 2.3:  Compositions of PDMSstar-PEGDA hydrogels used to study the effects of scaffold physical 
properties on SMC behavior.  As an example of the ratios presented, 95:5 refers to an overall 10% 
polymer solution in HBS-TEOA, 95% being PEGDA and 5% being PDMSstar.  For the last two combined 
formulations, the overall polymer concentration is again 10% in HBS-TEOA, half of which is the 3.4k 
formulation and half of which is the 6k formulation 
PEGDA 
MW 
(kDa) 
PDMSstarMA 
MW (kDa) 
PEGDA:PDMSstarMA 
  
3.4 0 100:0 
  1.8 95:5 
  1.8 80:20 
  5 95:5 
  7 99:1 
  7 80:20 
6 0 100:0 
  5 90:10 
  7 80:20 
3.4,6 5 99:1, 80:20 For these formulations, solutions were 
prepared in equal amounts of the ratios shown, 
half of the 3.4k formulation and half of the 6k 
formulation 
  5 80:20, 80:20 
   
 
 
 Constructs were cut into ring segments.  End segments were discarded.  Samples 
for biochemical analysis were snap frozen in liquid N2 and stored at -80°C until use.  
Samples designated for histological analysis were frozen in Tissue Tek media at -20°C.  
Samples for mechanical conditioning were rinsed with PBS and immediately tested for 
elastic modulus.  Quantitative histology was performed to examine ECM deposition and 
to test for 10T1/2 differentiation pathways.  In addition, ECM deposition was analyzed 
via biochemical analysis.  For simplicity in discussion, a condensed nomenclature will 
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be used.  For example, 3.4 1.8/5 will refer to a hydrogel from 3.4kDa PEGDA and 
1.8kDa PDMSstar in a 95:5 ratio. 
 
7.3 Results and Discussion 
  
 Final mechanical results are shown in Figure 7.1.  The elastic modulus 
distribution did not yield expected results.  As a group, the 3.4 kDa PEGDA hydrogels 
generally agree with previously seen trends.  The 6 kDa PEGDA hydrogel formulations, 
however, trend higher than expected, and are not significantly different from the 3.4 kDa 
formulations.  Therefore, the results analysis will focus on the 3.4 kDa formulations and 
relate observed trends to inorganic content. 
 Figure 7.2 shows the biochemical analysis of overall collagen content.  In 
general, an increase in PDMS content increased overall collagen production.  3.4k 5/5, 
3.4k 1.8/10 and 3.4k 7/20 have the highest overall collagen production and are 
significantly different from the other formulations.  3.4k 7/1, 3.4k 1.8/5 and 3.4k 1.8/20 
showed similar collagen numbers and are significantly different from the pure 3.4k 
control. 
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Figure 7.1:  Mechanical data for PDMSstar-PEG co-hydrogels after experimental run 
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Figure 7.2:  Total collagen production from biochemical analysis 
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 Figure 7.3 shows the elastin production determined from the biochemical assay.  
In general, formulations did not show a significant difference in overall elastin 
production.  3.4k 7/1 was an exception, showing significant difference from the other 
formulations.  3.4k 7/20 exhibited a higher average than the other formulations, but could 
not be statistically justified.  This could indicate higher MW PDMS content is beneficial 
for elastin production.  This slightly contradicts preliminary measurements which showed 
overall reduction in elastin deposition with any PDMS presence (72).  More work into the 
underlying signaling pathways would need to be performed to fully study these effects. 
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Figure 7.3:  Elastin production from biochemical analysis 
 
 Figure 7.4 shows quantitative immunostaining results for collagen deposition.  
The general trends agree with the biochemical analysis.  Increasing PDMS content 
appears to enhance collagen production.  However, standard deviations are too large to 
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draw statistical conclusions about the data.  Collagen I was enriched in the 3.4 1.8/5 
formulation.  For collagen II and III, the 20% PDMS content gels showed the highest 
levels in addition to the 0% control.  These are general trends as standard deviations are 
too large to draw statistical conclusions. 
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Figure 7.4:  Collagen production from quantitative histological staining 
   
 Mesenchymal stem cells have the ability to differentiate into a variety of cell lines 
including SMCs, osteoblasts, chondrocytes, adipocytes and myocytes.  Osteoblasts are 
present in bone tissue, chondrocytes are found in cartilage, adipocytes in fat tissue, and 
myocytes in cardiac muscle.  Each has different characteristic markers that can be 
identified to test for preferential differentiation.  For SMCs, osteoblasts, chondrocytes, 
adipocytes and myocytes, these markers are calponin h1, osteocalcein, collagen II, 
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AFABP and skeletal cardiac α-actin (sk/cd α-actin), respectively.  These markers (except 
collagen II) are presented in Figures 7.5 and 7.6. 
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Figure 7.5:  Differentiation markers for mesenchymal cell lines from quantitative histological 
staining 
 
 
 Standard deviations are too large to draw statistical conclusions.  However, some 
general trends are apparent.  Most important for TEVG implications are the 95:5 ratio 
formulations and their apparent enhanced expression of calponin h1.  The results for this 
particular ratio are in agreement with previously observed results as shown in Figure 7.7 
(72).  Further analysis into the underlying signaling pathways responsible for calponin h1 
upregulation needs to be performed to fully understand this apparent selectivity for 
SMCs. 
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Figure 7.6:  AFABP expression from quantitative histological staining 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7:  Mesenchymal cell differentiation markers from previous work (72) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSC Differentiation Markers 
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 For myocytes, the overall expression was low, with increasing PDMS content 
generally increasing expression, a trend opposite to the previous work with 6kDa PEG.  
The different PEG MW may also account for the differing trends.  For osteocalcein, 
previous data showed increasing PDMS content enhanced expression.  This general trend 
also appeared in this work, with lower MW PDMS showing greater enrichment.  From 
the previous work, PDMS presence reduced expression of AFABP.  This experiment 
isolates two formulations specifically which seem to limit AFABP expression, 
specifically 3.4 1.8/5 and 3.4 7/1, while higher PDMS content and the control gel showed 
higher presence of AFABP. 
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CHAPTER VIII 
CONCLUSIONS AND FUTURE WORK 
 
8.1 Vocal Fold Experiment 
 
8.1.1 Conclusions 
 
 Current results indicate differences in the interactions between certain 
proteoglycans and PVFfs.  The DS formulation was excluded from analysis because of 
its reduced elastic modulus.  Elastic modulus has a significant effect on cell behavior, 
and for this formulation, could not be excluded as an experimental variable.  
Specifically, HA, CSC and HS produced equivalent amounts of collagen.  However, 
CSC and HS produced a collagen I rich environment while HA was reduced in collagen 
I relative to CSC and HS.  Relative to the other two formulations, HA was enriched in 
collagen III.  In natural vocal fold tissue, generally the ECM is made up of equal parts of 
collagen I and III, with potential enrichment of collagen III.  Relative ratios of collagen 
types have a significant impact on the mechanical properties of the tissue, with collagen 
III rich environments being associated with more elastic tissue.  Preliminary analysis 
indicates a potential correlation between the ERK signaling transduction pathway, ECM 
production and SM α-actin expression, with enhanced ERK expression being associated 
with reduced SM α-actin deposition.  CSC and HS also showed increased expression of 
SM α-actin, which is generally associated with vocal fold scarring.  SM α-actin is 
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indicative of a transition from a fibroblast to a myofibroblast phenotype, which are 
present under tissue repair and scarring.  It can be concluded that different GAGs do 
influence VFf behavior, but more work will need to be done to more thoroughly probe 
the extent of this influence and how they may be optimized. 
 
8.2.2 Suggested Future Work 
 
 Suggested future work consists of an equivalent experiment which will include 
DS as a proteoglycan of interest.  The results from this formulation could not be 
included here for discussion because of the differences in that gel’s mechanical 
properties.  In order to systematically study all components that control cell behavior, the 
different relevant factors need to be decoupled so that specific conclusions may be 
drawn.  In addition, other components important in vocal fold tissue may be studied for 
any potential influence over cell behavior including fibronectin and fibrinogen.  Further 
work, including RT-PCR studies and Western blotting should be performed to better 
understand the ERK and PKC transduction pathways and how they affect ECM 
production.  RT-PCR can give a more in depth picture of the signaling pathways and 
how they are reacting to produce differences in ECM deposition and SM α-actin 
expression and how this might be prevented.  Western blotting can support histological 
staining results and improve statistical conclusions via enhanced sample size. 
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8.2 Bioreactor Experiments 
 
8.2.1 Conclusions 
 
 The initial bioreactor experiment utilized mature cells in a dual-layered 
configuration.  Both an EC layer and a SMC layer were created.  Cell migration between 
graft layers did not occur, allowing for conclusions from results obtained via histology, 
immunoblotting and gene expression to be applied to the medial SMC layer.  Results 
from this experiment show a strong correlation between EC presence and mechanical 
conditioning on both SMC differentiation markers and ECM deposition.  Results show 
that both components are independently important in ensuring a mature phenotype and 
maximizing elastin production.  Collagen I deposition appeared reduced by the presence 
of ECs, so more work studying the underlying signaling pathways for collagen 
production need to be performed to prevent this in future TEVGs.  Some limitations for 
this experiment hinder some areas of analysis.  Sample size, while consistent with other 
similar experiments, proved small, yielding large standard deviations, making 
distinctions between results for some formulations impossible due to statistical 
significance.  Also, the EC layer was synthesized as a 1mm thick 3-dimensional 
scaffold.  This is in contrast to the monolayer structure typically seen in native vascular 
tissue.  Future experiments may need to refine the luminal layer design to more closely 
mimic the natural EC monolayer. 
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 The next experiment introduced the adventitial fibroblast layer with an EC layer, 
while still 3-dimensional in orientation, reduced to 0.5mm thick.  Also, MSCs were 
utilized to investigate inter-cellular communication and mechanical conditioning affect 
the differentiation of progenitor cells.  The quantitative histological staining presented 
here shows some results consistent with previous work with many major trends reversed.  
Like previous bioreactors, stainings showed localized deposition of matrix proteins.  
Also, migration of ECs did not occur in any significant amount.  The magnitudes of 
standard deviations and small sample size have not allowed for statistical conclusions to 
be made, but general trends can be observed.  EC presence appeared to reduce 
myocardin and calponin h1 expression.  Since they are binding partners, the trends 
between reactors would be expected to match, which they do here.  Contrary to previous 
results, EC presence under dynamic conditioning did not appear to reduce collagen I 
deposition.  Mechanical conditioning and EC presence appear to be more important than 
fibroblast presence, but further tri-layered studies will need to be performed to verify 
this.  Mesenchymal progenitor cells appear to react differently than mature SMCs to EC 
presence.  This may be either a function of the cell type, or a difference in the 3-
dimensional layout of the EC layer from the monolayer in natural tissue.  Co-culture 
conditions will need to be investigated further to determine the optimal conditions for 
progenitor cell culture. 
 Given the reversal of trends seen with the MSC experiment, a method to 
synthesize an EC monolayer to more closely mimic natural vascular tissue was created.  
Also, a return to mature SMCs was made to discover any potential signaling differences 
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seen from the initial RASMC experiment given the difference in the EC layer 
construction.  Preliminary studies indicate an influence of mechanical conditioning over 
both SMC phenotype and collagen production.  One limitation early vascular graft work 
has suffered from is the lack of a suitable and stable endothelium under dynamic 
conditioning.  The method presented here resulted in a stable EC layer with limited to no 
migration between graft layers.  Experiments were conducted with abrupt, high shear 
conditioning as well as longer term, low shear conditioning, with both methods yielding 
a stable and intact EC layer.  EC viability was also tested and confirmed through typical 
EC markers NOS, vWF and occluding.   
 Results from this experiment generally agreed with the initial mature cell line 
experiment.  Dynamic conditioning enhanced ECM production and increased SRF 
expression, which also led to enhanced calponin h1 expression, indicating a more mature 
phenotype.  These results are consistent with the initial study and show an ability to 
create a stable EC monolayer which closely mimics that of natural tissue.  One limit of 
the current study, especially in terms of the biochemical analyses is sample size.  The 
sample number used in this study is consistent with many similar studies, but yielded 
significant standard deviations, making comparisons between constructs difficult.  
Future studies will seek to increase samples for study to gain an enhanced understanding 
of the effects of mechanical conditioning. 
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8.2.2 Suggested Future Work 
 
 Further work can now be done by investigating the impact of an EC monolayer 
on MSCs in conjunction with mechanical conditioning.  More experiments need to be 
conducted to determine the role EC presence plays in MSC differentiation and if it 
differs from the results seen with mature cell lines.  Dynamic TEVG experiments may 
also begin to include investigation of changes in scaffold mechanical properties, 
specifically through the introduction of PDMSstar into the hydrogel framework.  The 95:5 
ratio of PEG:PDMSstar has been isolated to potentially enrich the SMC phenotype.  
Combining this formulation with EC presence and mechanical conditioning may further 
optimize the in vitro culture conditions.  In addition, more experiments investigating the 
role of biochemical stimuli on SMCs may be performed.  GAGs as well as other 
vascular components such as fibronectin and fibrinogen may have important 
implications in TEVG development.  Once the most relevant biochemical stimuli are 
identified under static conditions, they too may be combined with mechanical 
conditioning and multi-layered grafts to attempt to improve SMC performance and 
differentiation.  Future bioreactor experiments should attempt to include four samples 
per reactor rather than three.  This will strengthen the statistics and make significant 
differences more apparent.  Further experiments should be performed to more 
thoroughly analyze the impact of fibroblast presence and whether it is significant in 
SMC development and differentiation. 
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8.3 PDMSstar-PEG Hydrogels 
 
8.3.1 Conclusions  
 
 Unexpected mechanical property results prevented the 6 kDa formulations from 
being included in this analysis.  Some possible causes for the differences seen from 
previous measurements include incomplete crosslinking, excessive phase separation of 
PEG and PDMS in the precursor solutions and introduction of mechanical defects upon 
extraction from the cylindrical molds.  Further experiments will need to be performed to 
attempt to systematically alter the modulus and its effects on cell behavior.  This work, 
however, has successfully decoupled the effects of elastic modulus and the inorganic 
chemical environment. 
 Standard deviations and sample size limited the ability to draw statistical 
conclusions, but general trends could be observed.  Overall, increasing PDMS content 
increased total collagen deposition.  The most important implications for TEVGs are in 
vitro conditions that favor SMC differentiation.  The 95:5 ratio formulations for 
PEG:PDMSstar seem to enrich the SMC phenotype over other formulations.  Relative to 
other formulations, the 95:5 ratio gels also showed diminished expression for 
chondrocyte, adipocyte, myocyte and osteoblast phenotypes.  Results for osteocalcein 
also generally agreed with previous work showing with an increase in inorganic content 
enriching osteocalcein deposition.  Increasing inorganic content also generally decreased 
expression of the chondrocyte phenotype while increasing the myocyte phenotype. 
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8.3.2 Suggested Future Work 
 
 Further experiments which include 6k formulations will need to be performed.  
To span a wider range of elastic moduli, and incorporate this as a separate design 
variable, other MWs of PEGDA may be included through 10 kDa.  Formulations 
identified to enhance an SMC phenotype may be combined with other in vitro culture 
techniques, namely mechanical conditioning and cell co-culture, to attempt to optimize 
the development of TEVGs.  This experiment consisted of three samples per formulation.  
To enhance statistical results, at least four samples per formulation should be studied.  
Histological analysis of differentiation markers can also be verified via qRT-PCR and 
Western blots.  Western blots have an advantage over histological staining in that they 
include a larger sample size, enhancing statistical results.  Utilizing qRT-PCR will give 
more insight into the underlying signaling pathways responsible for MSC differentiation.  
By optimizing and combining the in vitro culture conditions including scaffold 
properties, mechanical conditioning and multi-layered cell-cell interactions, 10T1/2 
mesenchymal stem cells may be selectively driven to a mature SMC phenotype for use in 
TEVGs. 
 
8.4 General Conclusions 
 
 This work has shown an influence of a variety of in vitro culture conditions on 
cell behavior.  Identifying and optimizing each of these conditions and applying them to 
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tissue engineering studies may aid in the development of future vocal fold and TEVG 
experiments.  Specifically, the factors identified include: biochemical stimuli in the 
synthetic scaffold, mechanical conditioning, cell-cell interactions, and scaffold physical 
properties. 
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